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Rational design of nanoparticles to improve anticancer drug 
delivery 
By 
Belli Valentina 
 
ABSTRACT 
The need to improve current cancer therapies is a pivotal point in the drug 
delivery systems. A major challenge is to disclose new strategies that can 
combine the use of targeted nanoparticles (NPs) to the efficient delivery of 
chemotherapeutic agents in the vicinity of tumor masses, minimizing the side 
effects on healthy cells. To this purpose, a preliminary step is that of defining the 
optimal NP characteristics able to improve drug delivery at target tissues. 
However, these aspects need to be defined in suitable models that can actually 
mimic the main cell activities, including adhesion, migration and differentiation. 
These features are instead missed when cells are grown on flat plastic dishes, as 
it occurs in traditional two dimensional (2D) systems; thus, the 2D unnatural 
environment can provide inaccurate data, failing to predict the in vivo real cell 
response to NP treatments.  
In this context, the main goal of this thesis has been that of identifying the key 
parameters useful for a rational design of anticancer drug delivery systems. To 
this aim, the following issues have been addressed: 
- the effect of three dimensional (3D) extracellular matrix, made up of collagen 
type I, in controlling the diffusion and cellular uptake of NPs with variable size 
and surface charge; 
- the cytotoxic efficacy of biodegradable NPs to deliver the Doxorubicin (Dox) 
anticancer drug in three dimensional matrices, as a function of size; 
- the possibility to control “on demand” Dox release, in order to reach a more 
efficient tumor-specific targeting.   
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Results indicate that, in 3D environment, size, surface charge and 
functionalization are all crucial NP features that can modulate their ability to 
diffuse through the ECM and finally reach the cells. In parallel, the same 
properties also influence the cytotoxic effects and the cellular responses, with 
smaller sizes facilitating diffusion through the collagen matrix and increasing the 
efficiency of NP treatments.  
Finally, the covalent conjugation of Dox to NPs through cleavable linkers 
allowed obtaining a more controlled drug release. This type of nanocarrier was 
made specifically responsive to matrix metalloproteinase-2 (MMP2), which is 
known to be over-expressed in the tumor extracellular matrix, so that the drug 
release from NPs, as the relative cytotoxic effect, were specifically triggered by 
MMP2 cleavage.  
Altogether, the results obtained indicate that the physical-chemical characteristics 
of NPs and their behaviour in a 3D environment, that better mimics in vivo 
growth conditions, are crucial parameters that need to be taken into consideration 
for a more rational design of nanocarriers finalized to drug delivery in tumor 
tissues.  
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CHAPTER 1 
1.1. INTRODUCTION 
1.1.1. Nanoparticles in cancer therapy 
Conventional chemotherapeutic agents distribute non-specifically into the body, 
and thus can target both cancerous and normal cells. This non-specific drug 
distribution has two adverse effects: limits the therapeutic dose within target 
cells, and provides excessive toxicity to healthy cells, tissue and organs, thereby 
causing several unwanted side effects. These effects include hairloss, weakness 
and organ dysfunction and, altogether, lower the quality of the life of patients. 
Due to their versatility in targeting tissues, ability to access deep molecular 
targets and control drug release, the use of nanoparticles (NPs) is a promising 
approach to improve the modern drug delivery systems [1-7]. Over the last years, 
a large number of NP delivery systems has been developed for cancer treatment, 
including lipids (e.g. solid/lipid NPs, liposomes), polymers (e.g. biodegradable 
polymeric particles, dendrimers), inorganic materials (e.g. metal NPs, quantum 
dots), and biological materials (e.g. viral and albumin nanoparticles) [8-16] (Fig. 
1). In addition, NPs can be tailored to carry both drugs and imaging probes 
simultaneously, and can be designed to specifically target molecules of diseased 
tissues [3, 17]. Therefore, their advantages include enhanced solubility and 
stability of hydrophobic drugs, prolongation of circulation time, minimization of 
non-specific uptake, prevention of undesirable off-target and side effects, 
improvement of intracellular penetration, and targeting of specific cancer 
markers [18]. In addition, encapsulated molecules can be released from NPs in a 
controlled manner over time to maintain a drug concentration within a 
therapeutic window, or drug release can be triggered by a stimulus unique to the 
delivery site [19, 20]. Several studies underlined the great potentiality of these 
NP systems. For example, Xie and colleagues established that NPs made up of 
poly lactic-co-glycolic acid (PLGA)-loaded with curcumin can represent a 
promising approach for obtain a sustained and controlled drug delivery [21]. In 
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another study, Acharya and co-workers demonstrated the synergistic effect of 
dual drugs entrapped in polymeric NPs. The combined formulation resulted in 
enhanced cytotoxicity against leukemic K562 cells compared with the free drugs 
at a lower dose [22]. 
 
Figura 1. Example of different kind of nanocarriers for cancer detection [7].  
Despite these advancements on drug delivery, the efficiency of chemotherapy 
remains substantially limited by the resistance of cancer cells to anticancer drugs, 
a parameter that fluctuates significantly in different patients. This phenomenon, 
called multidrug resistance (MDR), is one of the major causes of treatment 
failure in cancer therapy, and is attributed to the decreased accumulation of drug 
in the tumor site and possibly to the role of the membrane P-glycoprotein in 
accelerating the drug efflux [23-25] (Fig. 2-C). To overcome the problem of 
efflux action of P-glycoprotein and sustain the drug effect, various drug delivery 
systems have been developed [26-28]. For instance, PLGA NP formulations 
capable of delivering the cytotoxic drug vincristine or the chemosensitizer 
verapamil, or their combination, were prepared by Song et al [29]. The results 
obtained showed that PLGA NPs simultaneously loaded with the anticancer drug 
and the chemosensitizer might provide a potentially favorable formulation for in 
vivo treatment of drug-resistant cancers, since this simultaneous administration 
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resulted highly efficient even on MCF-7/ADR cells resistant to vincristine. In 
other studies, an efficient and targeted delivery of antisense 
oligodeoxynucleotides using folic acid-conjugated hydroxypropyl-chitosan NPs 
was developed to reduce production of P-glycoprotein and overcome tumor drug 
resistance [30].  
Beside the control of drug efflux, another important aspect for improving the 
efficiency of drug delivery systems consists in controlling the relationships and 
the possible interactions that can be established between NPs and biological 
compounds after administration. Indeed, the physical and chemical properties of 
NPs, such as size, shape, surface charge and composition, can affect their 
interactions with several components of the blood flow and exert a strong effect 
on their extravasation and diffusion in tumor environment [2, 31-33]. Firstly, the 
surface of NPs can be designed either to attach specific ligands that can enhance 
their uptake by target tissues, or to increase the blood circulation half-life that 
consequently influences their distribution [34, 35]. Indeed, it is well known that 
NPs, when administered into the blood, are rapidly cleared and taken up within 
few time by the cells of the reticulo-endothelial system (RES)/mononuclear 
phagocyte system (MPS) present in the body, and remain particularly distributed 
in liver, lungs, spleen, and bone marrow [35-37]. NP uptake can be optimized 
also by functionalization of NP surface that is by addition of chemical functional 
groups. This approach is often used to add modifications that can improve the 
new NP formulations with drug controllable release, a parameter that in turn can 
optimize the concentration of the active drug at the sites of action. For instance, 
to extend the circulation time of NPs in vivo, uncharged hydrophilic polymers 
such as polyethylene glycol (PEG) are often conjugated to the surface of particles 
for “stealthing” [25, 38, 39]. By preventing opsonisation, the addition of PEG 
drastically increases the blood half-life of all NPs, regardless of their surface 
charge. Furthermore, the shape, density and length of the PEG chains can be 
modified and exert various effects on the rate of clearance. For example, it has 
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been shown that increasing the molecular weight of PEG chains above 2 kDa 
increases the half-life of the PEGylated particles [36].  
In addition to surface functionalization, blood half-life and cellular uptake also 
depends on NP shape and size. For instant, Chithrani et al demonstrated the 
important role of particle shape and potentially curvature on NP cellular 
internalization [40]. These authors reported that 14 and 75 nm spherical 
nanoparticles were up-taken by cells 3.75–5 times more efficiently than 74-by-14 
nm rod-shaped particles. It was hypothesized that this significant difference 
could be due to the different particle curvature that can affect the contact area 
with receptors on cell membrane and the distribution of targeting ligands on NP 
surface. Together with NP surface conjugations and shape, NP diameter is an 
additional important determinant for NP diffusion and drug release [41]. Particles 
with small diameter allow overcoming the biological barriers and can achieve a 
better cellular uptake than bigger ones [42, 43]. Indeed, NPs larger than 400 nm 
can not be simply unable to diffuse through the tumor interstitium in sufficient 
quantities to have any clinical or therapeutic effect [37, 44]. 
Hence, all physical and chemical features of NPs have a profound influence also 
on their extravasation from blood vessels. In this view, it is possible to exploit 
passive accumulation of NPs in tumor tissues, due to morphological differences 
existing between healthy and sick tissues. In this regard, an overview of the 
extracellular matrix focussing on tumor microenvironment is needed to 
understand the basis of the new strategies that are currently designed to improve 
the effects of NPs in cancer therapy.  
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1.1.2. The effects of tumor extracellular matrix on NP diffusion  
In a living organism, all cell types are in contact with the extracellular matrix 
(ECM), a complex and dynamic network of macromolecules with different 
physical and chemical properties. The ECM consists of numerous molecules 
classified traditionally as collagens, elastin, microfibrillar proteins, proteoglycans 
(including hyaluronan), and non-collagenous glycoproteins. The ECM is a 
dynamic and versatile compartment and, by modulating the production, 
degradation and remodelling of its components, it supports organ development, 
function, repairing and consequent tissue homeostasis [45, 46]. On the basis of 
the organization of different components, the ECM molecular network is detailed 
for each tissue and reflects the specific functions required for those cell types. 
Moreover, the diversity and sophistication of ECM components confers specific 
and diverse physical, biochemical and biomechanical characteristics. Physical 
properties such as porosity, rigidity and insolubility are essential for the 
scaffolding role in supporting tissue structure and integrity, and also contribute to 
cell division and migration [45]. The ECM cleavage and remodelling can 
promote cell movement through the formation of guidelines on which cells can 
migrate. In addition, the orientation of ECM components, such as collagen fibers, 
can profoundly influence the directed migration of cells, by potentiating growth 
factor receptor signalling. Indeed, the ECM can bind to a myriad of growth factor 
and, in so doing, it limits the diffuse range and accessibility of ligands to their 
cognate receptors. A key concept regarding the ECM environment concerns how 
its bio-chemical and bio-mechanical properties can influence NP passage into 
cancer cells and consequently their effects on these cells [47, 48]. This aspect 
becomes even more evident when considering that cell–ECM connection is a 
reciprocal interaction in which cells continually remodel the ECM present in 
their microenvironment, and these dynamic modifications affect NP crossing. 
Despite multiple regulatory mechanisms, ECM dynamics can go skew when 
activities of ECM remodelling proteins are uncontrolled and deregulated, 
resulting in devastating consequences manifested in various human diseases [49]. 
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For example, various collagens, including collagen I, II, III, V, and IX, show 
increased deposition during tumor formation [50]. As consequence of the 
changes in its composition, the architecture of tumor-associated ECM is 
fundamentally different from that typical of the normal tissue. Indeed, consistent 
with the changes in ECM composition and topography, expression of many ECM 
remodelling enzymes is often deregulated in human cancers, making 
advantageous the use of these molecules as targeting moieties. For example, 
heparanases, sulfatases, permeability mediators, such as vascular endothelial 
growth factor (VEGF), bradykinin (BK), prostaglandins (PGs), nitric oxide (NO) 
and, most notably, many metalloproteases (MMPs), are frequently overexpressed 
in various cancers [51-53] (Fig. 2-A). Among others, one of the earlier events in 
tumor progression is the generation of activated fibroblasts, which contributes to 
abnormal ECM build-up and deregulated expression of ECM remodelling 
enzymes. Continuing, in late-stage, immune cells are often recruited to tumor 
sites to promote tumor-associated angiogenesis (formation of new blood vessels 
from existing ones). Hence, the abnormal ECM dynamics promote cancer cell 
proliferation, loss of cell differentiation and invasion, playing essential role in 
cancer progression (Fig. 2). This irregular condition promotes a unique 
anatomical and pathophysiological architecture. For instance, the blood vessels in 
a solid tumor are irregular in shape, dilated, leaky or defective, and the 
endothelial cells are poorly aligned or disorganized with large fenestrations (Fig. 
2-D). These large gaps facilitate selective extravasation of NPs from the 
surrounding vessels into the tumor [54, 55]. 
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Figure 2. The tumor environment. A) Angiogenesis due to tumor cells releasing factors, such as 
VEGF, BK, PK and NO that stimulate the production of new blood vessels. B) Tumor bulk C) 
Multidrug resistence effect, probably due to the role of the membrane P-glycoprotein in 
accelerating the drug efflux. D) Enhanced permeability and retection effect due to the combined 
effect of “leaky” defective vascular architecture and poor tumor lymphatic drainage [3].  
Furthermore, the impaired lymphatic drainage of solid tumor tissue facilitates the 
retention of the accumulated NPs, allowing them to release drugs in the vicinity 
of the target site [55]. This phenomenon is well-known as “Enhanced 
Permeability and Retention (EPR)” effect (Fig. 3). This passive targeting is 
widely utilized in biomedical applications, since tumor morphology facilitate the 
accumulation of NPs in sick tissues [56, 57]. Generally, NP-based carriers with 
diameter less than 200 nm are effective for passive targeted drug delivery to a 
solid tumor [9].  
However, although passive targeting is at the basis of clinical cancer therapy, it 
displays several limitations. For instance, the exploitation of EPR effect is not 
feasible in all tumors, because the degree of vascularization and porosity of 
tumor vessels can vary with the tumor type and status [57]. Moreover, tumors 
have a negative interstitium pressure gradient, which can substantially limits the 
convection of NPs from the intravascular to the extravascular space within the 
cancerous cell mass. One way to address these challenges is to program new 
formulations of smart NPs with active binding ability to specific ligands after 
extravasation. It is well know, in fact, that solid tumors often overexpress 
specific antigens on cancer cell surface or within the ECM [58, 59]. Finally, the 
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EPR effect is found to be pronounced when the nanocarrier delivery systems are 
designed to evade the MPS system, so that their circulation half-life in the blood 
is extended.  
 
 
 
Figure 3. Enhanced Permeability and Retection (EPR) effect: passive (A) and active targeting 
(B). The EPR effect ermitting accumulation of nanometer-sized particles in cancer cells. Blood 
vessels in tumor tissue have defective architecture with gaps as large as 200–1000 nm allowing 
nanoparticles to extravasate and accumulate inside the tumor tissue.  
1.1.3. Active targeting: cellular and extracellular marks 
To guide the NPs to the target site, the most common strategy is to conjugate on 
the NP surface selective markers that enable to interact with specific active 
components of tumor environment, such as the membrane of cancer cells or 
specific organelles inside these cells [60]. Many targeting moieties include 
antibodies or their fragments, peptides, nucleic acids (aptamers), polysaccharides 
(hyaluronic acid, HA), glycoproteins (transferrin) and small molecules (folate 
acid) [17, 61-66]. Although monoclonal antibodies (mAbs) have widely used as 
escort molecules for targeted delivery, several restrictions, as their large size and 
difficulty in conjugation to NPs, have hampered their uses. Thus, other smaller 
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ligands, such as peptides, have attracted greater attention in the last years. 
Generally, screening of potential protein ligands is typically performed using a 
combinatorial phage library, and this approach selects ligands that range from 
10–15 amino acids in length for their ability to selectively bind to tumor targets 
with high affinity [67-69]. Moreover, the capacity to link two or more markers 
upon NP surface can generate multivalent systems with the purpose of 
significantly increase the binding affinity of a particle toward a target cell, and 
optimize the accumulation of chemotherapics specifically in the tumor site, 
leaving healthy organs intact [70]  (Fig. 4).  
 
 
Figura 4. Example of multifunctional nanoparticles can be designed with a choice of drug 
delivery, tumor targeting ligands, molecular imaging with stealth properties for several 
applications [71]. 
A good example of this strategy was provided by Sun et al, who demonstrated 
that doxorubicin-linked to gold NPs via a poly (ethylene glycol) spacer and an 
acidabile hydrazone bond can potently be delivered to breast CSCs, drastically 
reducing their capacity of mammosphere formation and cancer initiation activity, 
and eliciting marked enhancement of tumor growth inhibition in murine models 
[72]. In addition, Yoo and Park designed model micelles formed by a copolymer 
of poly (D, L-lactic-co-glycolic acid) (PLGA) and PEG, where the doxorubicin 
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(DOX) was conjugates via chemical linkage to the PLGA, and the folate acid 
was added to the PEG chain. These particles exhibited increased cellular uptake, 
circulation time, and decreased cardiotoxicity. This last parameter indicated that 
the targeting moiety was able to differentiate between healthy and tumor tissue 
with greater specificity than untargeted DOX, while the increased cytotoxicity 
and cellular uptake showed that the folate-receptor actively internalized the 
conjugated particle into the cytoplasm [73]. Noteworthy, also transferrin-
conjugated NPs have been shown to inhibit cellular proliferation and tumor 
growth and to display sustained release profiles and increased cellular uptake. 
The effectiveness of the conjugated NPs is most likely due to their ability to be 
taken up by receptor-mediated endocytosis, which enhances the amount of drug 
delivered to tumor cells and limits the amount delivered to healthy cells [74, 75]. 
However, despite the functionalization of NP surface with specific ligands for 
membrane cancer cells can have extreme potentiality, in some cases it suffers 
several limitations. In fact, in some tumor types where the extracellular matrix is 
too dense, deep penetration of NPs is hampered [76]. Functionalized NPs are 
often much larger than conventional drugs used for cancer treatments, so that 
their penetration is adversed by the high tumor cell density and the high 
interstitial fluid pressure (IFP), and they often do not cross more than one or two 
layers [77]. This feature has been recently documented also by Popovic and co-
workers who, by using intravital microscopy, showed that upon injection of 
quantum dots with three different sizes (12, 60, 125 nm), only the smaller ones 
had the ability to penetrate, while the larger particles clustered in peri-vascular 
regions [78]. Similar findings have been reported by Dreher and colleagues who, 
by using dextran NPs with different diameter, demonstrated that both 
extravasation and penetration were efficient only for particles of small size [79]. 
These data strongly suggest that further attempts should be made to find an 
optimal NP size that can couple long-circulation properties with proper 
extravasation and penetration. To this goal, it is worth noting that designing 
ligands targeted to extracellular matrix or system with drug release “on demand” 
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could be helpful to overcome the penetration barrier. For example, the use of 
stimuli-sensitive nanocarriers, which allow release their contents in the vicinity 
of tumor, can keep low the molecular weight and permit the drug to penetrate 
deeply into the tumor (Fig. 5). These stimuli-responsive drug delivery systems 
have been designed for program drug release upon external or internal stimuli, 
including ultrasound, magnetic fields, heat, light, pH and specific enzyme 
activity [80-88]. For instance, in the case of drug delivery carriers containing 
magnetic NPs, Gang et al showed that magnetic (Fe(3)O(4)) poly epsilon-
caprolactone (PCL) NPs containing the anticancer drug gemcitabine can exert 
high therapeutic effects by delivering efficiently the drug to magnetically 
targeted tumor [89]. In addition, magnetic resonance probes were used to detect 
cancer, so that this system provides an optimal example for designing multistage 
NPs for targeted therapy and cancer detection. Karthik et al also furnished an 
excellent example of photo-responsive multifunctional magnetic nanoparticles 
(MNPs) based on the use of coumarin-based phototrigger for cell imaging and 
photo-controlled delivery of anticancer drugs [90]. Another important strategy 
includes the design a new formulations of NPs focussed to distinguish the acidic 
environment of solid tumors respect to that of normal tissues [91, 92]. The pH 
value of highly proliferating tissues is in fact generally comprised between 6.5 to 
7.2, due to the increased glycolysis and plasma membrane proton-pump activity 
of cancer cells [93, 94]. In addition, insufficient blood supply and poor lymphatic 
drainage also contribute to the acidity of the tumor microenvironment. Compared 
with the targeting of molecular biomarkers, the targeting of tumor extracellular 
pH value is insensitive to protein heterogeneity and is also not limited by the 
numbers of biomarkers present on the cell surface [95].  
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Figure 5. Approaches of drug release due to stimuli-sensitive nanocarriers (on left) and active 
targeting (on right) in cancer diagnosis [96].  
Typical examples of this strategy are polymeric NP systems that change their 
physical and chemical properties, such as their charges or TAT peptide exposure, 
in response to cleavage of pH-labile groups under the stimulus of local tumor pH 
value [95]. One example of pH-triggered drug delivery system was provided by 
the group of Bae, that developed a smart system made up of poly (L-
histidine)/PEG based polymeric micelles-loaded with doxorubicin. These mixed 
micelles were stable at pH above 7.4, while gradually destabilized below 7.0 due 
to the ionization of the polyHis block in the micelle core. The authors reported 
that this system retarded tumor growth and caused minimal weight loss in mice 
[97, 98]. An alternative strategy consists in functionalizing NP surface with 
specific components present at higher concentrations in the tumor extracellular 
environment respect to that of normal tissues. To this regard, particularly useful 
targets are some proteinases, such as heparanase and MMPs, nitric oxide (NO) 
and hyaluronic acid, that concentrated within and around the tumor mass [99-
102]. The heparanase activity, which degrades heparin sulphate (HS) chains 
covalently attached of heparan sulphate proteoglycans (HSPGs), had been 
reported in many metastatic tumors, and its expression was observed in a variety 
of malignant tumors to be correlated to the  malignant phenotype [59, 103]. 
  MMPs, family of zinc-dependent endopeptidases, also may play important roles 
in tumorigenesis and cancer cell progression, because they are able to digest all 
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the main components of basement membrane and ECM [104, 105]. Various 
MMP-sensitive substrates have been designed and showed stimulus 
responsiveness when used in drug delivery systems [106-108]. For example, Zhu 
et al used paclitaxel (PTX) as a model therapeutic, and synthesized a self-
assembling drug-polymer conjugate/prodrug, PEG2000-peptide-PTX, which 
contained the MMP2-cleavable octapeptide between PEG and PTX. This system 
demonstrated high potential for effective intracellular delivery of PTX into 
cancer cells [108].  
These new strategies could shift the paradigm of the traditional  approach  based 
on targeting markers specific to cancer cells surface (that can be highly variable 
among different tumor types) to a new one, that can be based on targeting 
specific extracellulary markers of ECM that are generally present  around a  
tumor mass. This shift could put the fundaments for a new targeting strategy that 
can be more generally advantageous for biomedical applications.  
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1.2. AIM OF THE PROJECT 
On the basis of this complex panorama, understanding the NP interactions with 
biological systems is a necessary step for developing NPs that can act more 
effectively as imaging and drug delivery agents. In this view, my work has been 
focused on pivotal aspects that determine the NP optimal features, that are: how 
physical-chemical properties, such as size, shape, functional groups and surface 
charge could affect the cellular response, in term of NP cellular uptake; and how 
the cytotoxic effects triggered by NPs-loaded with a widely chemotherapeutic 
drug, as doxorubicin (DOX), can vary according to different human cell lines. 
The traditional way to study NP-cell interactions is generally still based on 
following cell growth on flat dishes of polystyrene plastic in two-dimensional 
(2D) in vitro systems [40, 109-112], although 2D cultures impose highly 
unnatural behaviour and impose geometric and mechanical constraints to 
growing cells. However, within the body, the cells grow in a three dimensional 
(3D) ECM environment rich in type I collagen, fibrin, laminin, elastin, 
proteoglycans etc. Cells cultured in 3D matrices can thus better reflect the in vivo 
physiology than those cultured in 2D systems. For these reasons, several 
experiments were focussed to define NP uptake and cytotoxicity in different cell 
lines and to compare the results obtained in conventional 2D system to those 
obtained when cells were embedded in 3D collagen matrix.  
This thesis is organized in three sections, where each chapter focussed the 
attention on crucial aspects that overall put the groundwork for ameliorate the 
current strategies in cancer treatments: 
 The first chapter collects the experiments aimed to understand how NP 
features, such as size and surface charge, can affect NP diffusion and 
crossing through a 3D collagen matrix (the major component of ECM), 
where two different cell lines were embedded in. Possible interactions 
between NP properties and several components of ECM could, in fact, 
produce in the living organism a cellular response quite different from that 
showed in an in vitro 2D culture system. In particular, I investigated the 
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influence of (a) particle size, and (b) surface functionalization, on 
diffusion and cellular internalization of four different polystyrene NPs on 
primary human dermal fibroblasts (HDF), taken as a model of an healthy 
tissue,  and human fibrosarcoma (HT1080), taken as a model of a tumor 
tissue.  
 The second chapter discusses the suitability of biodegradable NPs loaded 
with a widely used chemotherapeutic agent, such as DOX, as a possible 
nanocarriers in drug delivery. Three NP formulations with different sizes, 
made up of two biodegradable co-polymers, such as poly (D, L-lactic-co-
glycolic acid) (PLGA) and poly (ethylene glycol) (PEG) were loaded with 
DOX, and accurately characterized. The effect of these NP preparations 
on cell uptake and toxicity was investigated in standard 2D cell cultures 
on HeLa and IGROV-1 cells, which were used as in vitro models of 
human cervix carcinoma and ovarian adenocarcinoma, respectively. The 
cytotoxicity of Dox-loaded PELGA NPs towards HeLa cells was also 
assessed in 3D collagen matrices, in which the NPs were confined in a 
region separated from the cells by a porous membrane, thus creating an 
initial Dox step-wise gradient [113].  
 Finally, the last chapter is focused to a rationale design of a novel 
nanocarrier able to safely carry DOX in tumor tissues in response to 
matrix metalloprotease-2 (MMP2) enzyme, which is over-expressed in 
ECM of tumors. Specifically, two MMP2 sensitive peptides were used as 
cleavable linkers between Dox and polyethylene glycol (PEG) to form a 
polymer-peptide-drug conjugate, working as a tumor-activated prodrug 
(TAP). The obtained TAP was then attached to the surface of 200 nm 
carboxyl-modified polystyrene model nanoparticles (NPs). The resulting 
TAP conjugated NPs were characterized in vitro for their release features 
at different MMP2 concentrations, in order to identify the minimum 
bioactive enzyme dose-response, and for their cytotoxic effect on three 
different human cell types, namely fibrosarcoma cell line (HT1080), 
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primary dermal fibroblasts (HDF) and umbilical vein endothelial cells 
(HUVECs), as models of tumor and healthy tissue, respectively. 
  
24 
 
1.3. REFERENCES 
1. Wang, E.C. and A.Z. Wang, Nanoparticles and their applications in cell and 
molecular biology. Integrative Biology, 2014. 6(1): p. 9-26. 
2. Davis, M.E., Z. Chen, and D.M. Shin, Nanoparticle therapeutics: an emerging 
treatment modality for cancer. Nature Reviews Drug Discovery, 2008. 7(9): p. 
771-782. 
3. Thakor, A.S. and S.S. Gambhir, Nanooncology: The Future of Cancer 
Diagnosis and Therapy. Ca-a Cancer Journal for Clinicians, 2013. 63(6): p. 395-
418. 
4. Subbiah, R., M. Veerapandian, and K.S. Yun, Nanoparticles: Functionalization 
and Multifunctional Applications in Biomedical Sciences. Current Medicinal 
Chemistry, 2010. 17(36): p. 4559-4577. 
5. Parhi, P., C. Mohanty, and S.K. Sahoo, Nanotechnology-based combinational 
drug delivery: an emerging approach for cancer therapy. Drug Discovery 
Today, 2012. 17(17-18): p. 1044-1052. 
6. Zhang, L., et al., Nanoparticles in medicine: Therapeutic applications and 
developments. Clinical Pharmacology & Therapeutics, 2008. 83(5): p. 761-769. 
7. Peer, D., et al., Nanocarriers as an emerging platform for cancer therapy. 
Nature Nanotechnology, 2007. 2(12): p. 751-760. 
8. Blasi, P., et al., Solid lipid nanoparticles for targeted brain drug delivery. 
Advanced Drug Delivery Reviews, 2007. 59(6): p. 454-477. 
9. Torchilin, V.P., Recent advances with liposomes as pharmaceutical carriers. 
Nature Reviews Drug Discovery, 2005. 4(2): p. 145-160. 
10. Allen, T.M. and P.R. Cullis, Liposomal drug delivery systems: From concept to 
clinical applications. Advanced Drug Delivery Reviews, 2013. 65(1): p. 36-48. 
11. Chan, J.M., et al., Polymeric Nanoparticles for Drug Delivery, in Cancer 
Nanotechnology: Methods and Protocols, S.R. Grobmyer and B.M. Moudgil, 
Editors. 2010. p. 163-175. 
12. Zhang, L., et al., Self-assembled lipid-polymer hybrid nanoparticles: A robust 
drug delivery platform. Acs Nano, 2008. 2(8): p. 1696-1702. 
13. Canfarotta, F. and S.A. Piletsky, Engineered Magnetic Nanoparticles for 
Biomedical Applications. Advanced Healthcare Materials, 2014. 3(2): p. 160-
175. 
14. Hu, C.-M.J., S. Aryal, and L. Zhang, Nanoparticle-assisted combination 
therapies for effective cancer treatment. Therapeutic Delivery, 2010. 1(2): p. 
323-334. 
15. Zhang, L., et al., Co-delivery of hydrophobic and hydrophilic drugs from 
nanoparticle-aptamer bioconjugates. Chemmedchem, 2007. 2(9): p. 1268-1271. 
16. MaHam, A., et al., Protein-Based Nanomedicine Platforms for Drug Delivery. 
Small, 2009. 5(15): p. 1706-1721. 
17. Ruoslahti, E., S.N. Bhatia, and M.J. Sailor, Targeting of drugs and 
nanoparticles to tumors. Journal of Cell Biology, 2010. 188(6): p. 759-768. 
18. Wilczewska, A.Z., et al., Nanoparticles as drug delivery systems. 
Pharmacological Reports, 2012. 64(5): p. 1020-1037. 
19. Moghimi, S.M., Recent developments in polymeric nanoparticle engineering 
and their applications in experimental and clinical oncology. Anti-cancer agents 
in medicinal chemistry, 2006. 6(6): p. 553-561. 
25 
 
20. Liu, J., et al., pH-Sensitive nano-systems for drug delivery in cancer therapy. 
Biotechnology Advances, (0). 
21. Xie, X., et al., PLGA Nanoparticles Improve the Oral Bioavailability of 
Curcumin in Rats: Characterizations and Mechanisms. Journal of Agricultural 
and Food Chemistry, 2011. 59(17): p. 9280-9289. 
22. Acharya, S. and S.K. Sahoo, Sustained targeting of Bcr-Abl plus leukemia cells 
by synergistic action of dual drug loaded nanoparticles and its implication for 
leukemia therapy. Biomaterials, 2011. 32(24): p. 5643-5662. 
23. Vauthier, C., et al., Drug delivery to resistant tumors: the potential of poly(alkyl 
cyanoacrylate) nanoparticles. Journal of Controlled Release, 2003. 93(2): p. 
151-160. 
24. Minko, T., L. Rodriguez-Rodriguez, and V. Pozharov, Nanotechnology 
approaches for personalized treatment of multidrug resistant cancers. Advanced 
Drug Delivery Reviews, 2013. 65(13-14): p. 1880-1895. 
25. Iyer, A.K., et al., Role of integrated cancer nanomedicine in overcoming drug 
resistance. Advanced Drug Delivery Reviews, 2013. 65(13-14): p. 1784-1802. 
26. Xiang, Q., et al., Cabozantinib reverses multidrug resistance of human 
hepatoma HepG2/adr cells by modulating the function of P-glycoprotein. Liver 
International, 2014: p. n/a-n/a. 
27. Sharom, F.J., Complex interplay between the P-glycoprotein multidrug efflux 
pump and the membrane: its role in modulating protein function. Frontiers in 
Oncology, 2014. 4. 
28. Roy, A., et al., Carboxymethylcellulose-Based and Docetaxel-Loaded 
Nanoparticles Circumvent P-Glycoprotein-Mediated Multidrug Resistance. 
Molecular Pharmaceutics, 2014. 
29. Song, X.R., et al., Reversion of multidrug resistance by co-encapsulation of 
vincristine and verapamil in PLGA nanoparticles. European Journal of 
Pharmaceutical Sciences, 2009. 37(3-4): p. 300-305. 
30. Wang, J., et al., Reversion of multidrug resistance by tumor targeted delivery of 
antisense oligodeoxynucleotides in hydroxypropyl-chitosan nanoparticles. 
Biomaterials, 2010. 31(15): p. 4426-4433. 
31. Lundqvist, M., et al., Nanoparticle size and surface properties determine the 
protein corona with possible implications for biological impacts. Proceedings of 
the National Academy of Sciences of the United States of America, 2008. 
105(38): p. 14265-14270. 
32. Monopoli, M.P., et al., Physical-Chemical Aspects of Protein Corona: 
Relevance to in Vitro and in Vivo Biological Impacts of Nanoparticles. Journal 
of the American Chemical Society, 2011. 133(8): p. 2525-2534. 
33. Nel, A.E., et al., Understanding biophysicochemical interactions at the nano-bio 
interface. Nature Materials, 2009. 8(7): p. 543-557. 
34. Nativo, P., I.A. Prior, and M. Brust, Uptake and intracellular fate of surface-
modified gold nanoparticles. Acs Nano, 2008. 2(8): p. 1639-1644. 
35. Moghimi, S.M., A.C. Hunter, and J.C. Murray, Long-circulating and target-
specific nanoparticles: Theory to practice. Pharmacological Reviews, 2001. 
53(2): p. 283-318. 
36. Owens, D.E. and N.A. Peppas, Opsonization, biodistribution, and 
pharmacokinetics of polymeric nanoparticles. International Journal of 
Pharmaceutics, 2006. 307(1): p. 93-102. 
26 
 
37. Alexis, F., et al., Factors affecting the clearance and biodistribution of 
polymeric nanoparticles. Molecular Pharmaceutics, 2008. 5(4): p. 505-515. 
38. Veronese, F.M. and G. Pasut, PEGylation, successful approach to drug delivery. 
Drug Discovery Today, 2005. 10(21): p. 1451-1458. 
39. Dobrovolskaia, M.A. and S.E. McNeil, Immunological properties of engineered 
nanomaterials. Nature Nanotechnology, 2007. 2(8): p. 469-478. 
40. Chithrani, B.D., A.A. Ghazani, and W.C.W. Chan, Determining the size and 
shape dependence of gold nanoparticle uptake into mammalian cells. Nano 
Letters, 2006. 6(4): p. 662-668. 
41. Steichen, S.D., M. Caldorera-Moore, and N.A. Peppas, A review of current 
nanoparticle and targeting moieties for the delivery of cancer therapeutics. 
European Journal of Pharmaceutical Sciences, 2013. 48(3): p. 416-427. 
42. Brigger, I., C. Dubernet, and P. Couvreur, Nanoparticles in cancer therapy and 
diagnosis. Advanced Drug Delivery Reviews, 2002. 54(5): p. 631-651. 
43. Goodman, T.T., P.L. Olive, and S.H. Pun, Increased nanoparticle penetration in 
collagenase-treated multicellullar spheroids. International Journal of 
Nanomedicine, 2007. 2(2): p. 265-274. 
44. Gullotti, E. and Y. Yeo, Extracellularly Activated Nanocarriers: A New 
Paradigm of Tumor Targeted Drug Delivery. Molecular Pharmaceutics, 2009. 
6(4): p. 1041-1051. 
45. Lu, P., et al., Extracellular Matrix Degradation and Remodeling in Development 
and Disease. Cold Spring Harbor Perspectives in Biology, 2011. 3(12). 
46. Muiznieks, L.D. and F.W. Keeley, Molecular assembly and mechanical 
properties of the extracellular matrix: A fibrous protein perspective. Biochimica 
Et Biophysica Acta-Molecular Basis of Disease, 2013. 1832(7): p. 866-875. 
47. Stylianopoulos, T., et al., Diffusion Anisotropy in Collagen Gels and Tumors: 
The Effect of Fiber Network Orientation. Biophysical Journal, 2010. 99(10): p. 
3119-3128. 
48. Lieleg, O., R.M. Baumgaertel, and A.R. Bausch, Selective Filtering of Particles 
by the Extracellular Matrix: An Electrostatic Bandpass. Biophysical Journal, 
2009. 97(6): p. 1569-1577. 
49. Muschler, J. and C.H. Streuli, Cell-Matrix Interactions in Mammary Gland 
Development and Breast Cancer. Cold Spring Harbor Perspectives in Biology, 
2010. 2(10). 
50. Egeblad, M., M.G. Rasch, and V.M. Weaver, Dynamic interplay between the 
collagen scaffold and tumor evolution. Current Opinion in Cell Biology, 2010. 
22(5): p. 697-706. 
51. Ilan, N., M. Elkin, and I. Vlodavsky, Regulation, function and clinical 
significance of heparanase in cancer metastasis and angiogenesis. International 
Journal of Biochemistry & Cell Biology, 2006. 38(12): p. 2018-2039. 
52. Page-McCaw, A., A.J. Ewald, and Z. Werb, Matrix metalloproteinases and the 
regulation of tissue remodelling. Nature Reviews Molecular Cell Biology, 2007. 
8(3): p. 221-233. 
53. Kessenbrock, K., V. Plaks, and Z. Werb, Matrix Metalloproteinases: Regulators 
of the Tumor Microenvironment. Cell, 2010. 141(1): p. 52-67. 
54. Fang, J., H. Nakamura, and H. Maeda, The EPR effect: Unique features of tumor 
blood vessels for drug delivery, factors involved, and limitations and 
27 
 
augmentation of the effect. Advanced Drug Delivery Reviews, 2011. 63(3): p. 
136-151. 
55. Greish, K., et al., Enhanced Permeability and Retention (EPR) Effect and 
Tumor-Selective Delivery of Anticancer Drugs. Delivery of Protein and Peptide 
Drugs in Cancer. 2006. 37-52. 
56. Danhier, F., O. Feron, and V. Preat, To exploit the tumor microenvironment: 
Passive and active tumor targeting of nanocarriers for anti-cancer drug 
delivery. Journal of Controlled Release, 2010. 148(2): p. 135-146. 
57. Maeda, H., Macromolecular therapeutics in cancer treatment: The EPR effect 
and beyond. Journal of Controlled Release, 2012. 164(2): p. 138-144. 
58. Li, M.-H., et al., Dendrimer-based multivalent methotrexates as dual acting 
nanoconjugates for cancer cell targeting. European Journal of Medicinal 
Chemistry, 2012. 47: p. 560-572. 
59. Vlodavsky, I., et al., Mammalian heparanase: involvement in cancer metastasis, 
angiogenesis and normal development. Seminars in Cancer Biology, 2002. 
12(2): p. 121-129. 
60. Haley, B. and E. Frenkel, Nanoparticles for drug delivery in cancer treatment. 
Urologic Oncology-Seminars and Original Investigations, 2008. 26(1): p. 57-64. 
61. Chung, Y.-I., et al., The effect of surface functionalization of PLGA 
nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting. 
Journal of Controlled Release, 2010. 143(3): p. 374-382. 
62. Kim, E., et al., Prostate cancer cell death produced by the co-delivery of Bcl-xL 
shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials, 
2010. 31(16): p. 4592-4599. 
63. Jiang, S., et al., Preparation, characterization, and antitumor activities of folate-
decorated docetaxel-loaded human serum albumin nanoparticles. Drug 
Delivery. 0(0): p. 1-8. 
64. Dassie, J.P. and P.H. Giangrande, Current progress on aptamer-targeted 
oligonucleotide therapeutics. Therapeutic Delivery, 2013. 4(12): p. 1527-1546. 
65. Pang, J., et al., Folate-conjugated hybrid SBA-15 particles for targeted 
anticancer drug delivery. Journal of Colloid and Interface Science, 2013. 395: p. 
31-39. 
66. Hong, G.-b., J.-x. Zhou, and R.-x. Yuan, Folate-targeted polymeric micelles 
loaded with ultrasmall superparamagnetic iron oxide: combined small size and 
high MRI sensitivity. International Journal of Nanomedicine, 2012. 7: p. 2863-
2872. 
67. Brissette, R., J.K.A. Prendergast, and N.I. Goldstein, Identification of cancer 
targets and therapeutics using phage display. Current Opinion in Drug 
Discovery & Development, 2006. 9(3): p. 363-369. 
68. Krag, D.N., et al., Selection of tumor-binding ligands in cancer patients with 
phage display libraries (vol 66, pg 7724, 2006). Cancer Research, 2006. 66(17): 
p. 8925-8925. 
69. Fang, B., et al., A novel cell-penetrating peptide TAT-A1 delivers siRNA into 
tumor cells selectively. Biochimie, 2013. 95(2): p. 251-257. 
70. Montet, X., et al., Multivalent effects of RGD peptides obtained by nanoparticle 
display. Journal of Medicinal Chemistry, 2006. 49(20): p. 6087-6093. 
28 
 
71. Babu, A., et al., Nanodrug Delivery Systems: A Promising Technology for 
Detection, Diagnosis, and Treatment of Cancer. AAPS PharmSciTech, 2014: p. 
1-13. 
72. Sun, T.-M., et al., Cancer stem cell therapy using doxorubicin conjugated to 
gold nanoparticles via hydrazone bonds. Biomaterials, 2014. 35(2): p. 836-845. 
73. Yoo, H.S. and T.G. Park, Folate receptor targeted biodegradable polymeric 
doxorubicin micelles. Journal of Controlled Release, 2004. 96(2): p. 273-283. 
74. Sahoo, S.K. and V. Labhasetwar, Enhanced Antiproliferative Activity of 
Transferrin-Conjugated Paclitaxel-Loaded Nanoparticles Is Mediated via 
Sustained Intracellular Drug Retention. Molecular Pharmaceutics, 2005. 2(5): p. 
373-383. 
75. Sahoo, S.K., W. Ma, and V. Labhasetwar, Efficacy of transferrin-conjugated 
paclitaxel-loaded nanoparticles in a murine model of prostate cancer. 
International Journal of Cancer, 2004. 112(2): p. 335-340. 
76. Wong, C., et al., Multistage nanoparticle delivery system for deep penetration 
into tumor tissue. Proceedings of the National Academy of Sciences of the 
United States of America, 2011. 108(6): p. 2426-2431. 
77. Lammers, T., et al., Drug targeting to tumors: Principles, pitfalls and (pre-) 
clinical progress. Journal of Controlled Release, 2012. 161(2): p. 175-187. 
78. Popovic, Z., et al., A Nanoparticle Size Series for In Vivo Fluorescence Imaging. 
Angewandte Chemie-International Edition, 2010. 49(46): p. 8649-8652. 
79. Dreher, M.R., et al., Tumor vascular permeability, accumulation, and 
penetration of macromolecular drug carriers. Journal of the National Cancer 
Institute, 2006. 98(5): p. 335-344. 
80. Lim, E.-K., et al., Delivery of Cancer Therapeutics Using Nanotechnology. 
Pharmaceutics, 2013. 5(2): p. 294-317. 
81. Vivero-Escoto, J.L., et al., Photoinduced Intracellular Controlled Release Drug 
Delivery in Human Cells by Gold-Capped Mesoporous Silica Nanosphere. 
Journal of the American Chemical Society, 2009. 131(10): p. 3462-+. 
82. Gary-Bobo, M., et al., Multifunctionalized mesoporous silica nanoparticles for 
the in vitro treatment of retinoblastoma: Drug delivery, one and two-photon 
photodynamic therapy. International Journal of Pharmaceutics, 2012. 432(1-2): 
p. 99-104. 
83. Lee, J.-H., et al., On-Demand Drug Release System for InVivo Cancer 
Treatment through Self-Assembled Magnetic Nanoparticles. Angewandte 
Chemie-International Edition, 2013. 52(16): p. 4384-4388. 
84. Katagiri, K., et al., Magnetoresponsive On-Demand Release of Hybrid 
Liposomes Formed from Fe3O4 Nanoparticles and Thermosensitive Block 
Copolymers. Small, 2011. 7(12): p. 1683-1689. 
85. Tachibana, K. and S. Tachibana, The use of ultrasound for drug delivery. 
Echocardiography-a Journal of Cardiovascular Ultrasound and Allied 
Techniques, 2001. 18(4): p. 323-328. 
86. Felber, A.E., M.-H. Dufresne, and J.-C. Leroux, pH-sensitive vesicles, polymeric 
micelles, and nanospheres prepared with polycarboxylates. Advanced Drug 
Delivery Reviews, 2012. 64(11): p. 979-992. 
87. Makhof, A., Y. Tozuka, and H. Takeuchi, pH-Sensitive nanospheres for colon-
specific drug delivery in experimentally induced colitis rat model. European 
Journal of Pharmaceutics and Biopharmaceutics, 2009. 72(1): p. 1-8. 
29 
 
88. Soppimath, K.S., et al., Multifunctional core/shell nanoparticles self-assembled 
from pH-induced thermosensitive polymers for targeted intracellular anticancer 
drug delivery. Advanced Functional Materials, 2007. 17(3): p. 355-362. 
89. Gang, J., et al., Magnetic poly ε-caprolactone nanoparticles containing Fe3O4 
and gemcitabine enhance anti-tumor effect in pancreatic cancer xenograft 
mouse model. Journal of Drug Targeting, 2007. 15(6): p. 445-453. 
90. Karthik, S., et al., Photoresponsive Coumarin-Tethered Multifunctional 
Magnetic Nanoparticles for Release of Anticancer Drug. Acs Applied Materials 
& Interfaces, 2013. 5(11): p. 5232-5238. 
91. Callahan, D.J., et al., Triple Stimulus-Responsive Polypeptide Nanoparticles 
That Enhance Intratumoral Spatial Distribution. Nano Letters, 2012. 12(4): p. 
2165-2170. 
92. Manzoor, A.A., et al., Overcoming Limitations in Nanoparticle Drug Delivery: 
Triggered, Intravascular Release to Improve Drug Penetration into Tumors. 
Cancer Research, 2012. 72(21): p. 5566-5575. 
93. Barar, J. and Y. Omidi, Dysregulated pH in Tumor Microenvironment 
Checkmates Cancer Therapy. BioImpacts: BI, 2013. 3(4): p. 149. 
94. Kato, Y., et al., Acidic extracellular microenvironment and cancer. Cancer Cell 
International, 2013. 13. 
95. Zhao, Z., et al., A Controlled-Release Nanocarrier with Extracellular pH Value 
Driven Tumor Targeting and Translocation for Drug Delivery. Angewandte 
Chemie-International Edition, 2013. 52(29): p. 7487-7491. 
96. Park, K., Polysaccharide-based near-infrared fluorescence nanoprobes for 
cancer diagnosis. Quantitative imaging in medicine and surgery, 2012. 2(2): p. 
106-13. 
97. Kim, K.S., et al., A cancer-recognizable MRI contrast agents using pH-
responsive polymeric micelle. Biomaterials, 2014. 35(1): p. 337-343. 
98. Lee, Y.J., et al., pH-Sensitive Polymeric Micelle-Based pH Probe for Detecting 
and Imaging Acidic Biological Environments. Biomacromolecules, 2012. 13(9): 
p. 2945-2951. 
99. Egeblad, M. and Z. Werb, New functions for the matrix metalloproteinases in 
cancer progression. Nature Reviews Cancer, 2002. 2(3): p. 161-174. 
100. McKenzie, E.A., Heparanase: a target for drug discovery in cancer and 
inflammation. British Journal of Pharmacology, 2007. 151(1): p. 1-14. 
101. Gialeli, C., A.D. Theocharis, and N.K. Karamanos, Roles of matrix 
metalloproteinases in cancer progression and their pharmacological targeting. 
Febs Journal, 2011. 278(1): p. 16-27. 
102. Arpicco, S., et al., Hyaluronic Acid Conjugates as Vectors for the Active 
Targeting of Drugs, Genes and Nanocomposites in Cancer Treatment. 
Molecules, 2014. 19(3): p. 3193-3230. 
103. Vlodavsky, I., et al., Significance of heparanase in cancer and inflammation. 
Cancer microenvironment : official journal of the International Cancer 
Microenvironment Society, 2012. 5(2): p. 115-32. 
104. Curran, S. and G.I. Murray, Matrix metalloproteinases: molecular aspects of 
their roles in tumour invasion and metastasis. European Journal of Cancer, 
2000. 36(13): p. 1621-1630. 
30 
 
105. Vihinen, P., R. Ala-aho, and V.M. Kahari, Matrix metalloproteinases as 
therapeutic targets in cancer. Current Cancer Drug Targets, 2005. 5(3): p. 203-
220. 
106. Zhu, L., P. Kate, and V.P. Torchilin, Matrix Metalloprotease 2-Responsive 
Multifunctional Liposomal Nanocarrier for Enhanced Tumor Targeting. Acs 
Nano, 2012. 6(4): p. 3491-3498. 
107. Rizzi, L., et al., Novel biotinylated bile acid amphiphiles: Micellar aggregates 
formation and interaction with hepatocytes. Organic & Biomolecular Chemistry, 
2011. 9(8): p. 2899-2905. 
108. Zhu, L., et al., Enhanced anticancer activity of nanopreparation containing an 
MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety. Proceedings 
of the National Academy of Sciences of the United States of America, 2013. 
110(42): p. 17047-17052. 
109. Jiang, W., et al., Nanoparticle-mediated cellular response is size-dependent. 
Nature Nanotechnology, 2008. 3(3): p. 145-150. 
110. Cartiera, M.S., et al., The uptake and intracellular fate of PLGA nanoparticles in 
epithelial cells. Biomaterials, 2009. 30(14): p. 2790-2798. 
111. Lunov, O., et al., Differential Uptake of Functionalized Polystyrene 
Nanoparticles by Human Macrophages and a Monocytic Cell Line. Acs Nano, 
2011. 5(3): p. 1657-1669. 
112. Rancan, F., et al., Skin Penetration and Cellular Uptake of Amorphous Silica 
Nanoparticles with Variable Size, Surface Functionalization, and Colloidal 
Stability. Acs Nano, 2012. 6(8): p. 6829-6842. 
113. Biondi, M., et al., Sub-100 nm biodegradable nanoparticles: in vitro release 
features and toxicity testing in 2D and 3D cell cultures. Nanotechnology, 2013. 
24(4). 
 
 
  
31 
 
CHAPTER 2 
 
Nanoparticle size and surface charge as key factors in 3D matrix 
cellular uptake 
 
2.1. ABSTRACT 
Until recently, basic research, developed for testing the performance of 
nanoparticles (NPs) and the efficiency of novel anti-cancer drug, was generally 
performed on cells grown on two dimensional (2D) substrates, such as plastic or 
glass. However, this unnatural condition likely forces cells to adjust to artificially 
flat and rigid surfaces, generating data misleading that could be interpreted in a 
wrong way. Hence, the need to develop a new type of in vitro model that better 
mimics the three dimensional (3D) environment in which in vivo cells reside. 
This context is essential either for better understanding how NPs diffuse in a 
more complex environment, namely the extracellular matrix (ECM), and for 
predicting the particle properties that drive their delivery to cells. Indeed, the 
diffusion of NPs depends not only on their physico-chemical properties, 
including size, surface charge and functionalization as well as from the features 
typical of ECM. To shed light on this context, we investigated the effects of NP 
size and surface charge on their diffusion and cellular uptake in 3D scaffold, 
made up of a major component of ECM, as collagen type I. Two different cell 
types, primary human dermal fibroblast (HDF) and human fibrosarcoma 
(HT1080) were embedded in this dense network of fibers, in order to mimic the 
natural environment of healthy and tumor tissues, respectively. Cell behaviour in 
the 3D collagen gel was investigated and compared to cells grown on 2D glass 
coverslips. Moreover, cell response to polystyrene nanoparticles (PS-NPs) was 
also evaluated as a function of NP size (44 and 100 nm), surface 
functionalization (-NH2 and –COOH) and diffusion through the 3D collagen 
matrix. Results were compared among cell types and with 2D cell culture 
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conditions. Furthermore, experimental data were used to develop a descriptive 
mathematical model able to explain NP uptake kinetics in 3D matrices. 
In summary, results showed that PS-NPs with small size and positive surface 
charge had a greater ability to diffuse in a complex matrix and higher capacity to 
be internalized by cells, suggesting that these two features should be considered 
in the rational design of NP for biomedical applications.  
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2.2. INTRODUCTION 
Recent advances in nanotechnology have led to the development of nanosized 
particles with controlled size and surface charge, which are promising in cancer 
detection and treatment [1-4]. To this aim, the diffusion of nanoparticles (NPs) in 
the extracellular matrix (ECM) is crucial to recognize the target cell population 
and release the therapeutic agent(s) locally, or mainly, in tumor tissues. The 
ECM is mainly composed of collagen, elastin, proteoglycans (e.g., hyaluronic 
acid) and non-collagenous glycoproteins, which form a three-dimensional (3D) 
network enclosing cells according to an organ-specific manner [5-7]. 
Furthermore, these molecules contribute either to control cellular activities such 
as adhesion, migration, proliferation, differentiation and survival, but also can 
have an effect on NP diffusion [8-11]. Nevertheless, the traditional way to study 
NP-cell interactions still consists in cellular adhesion on flat dishes of 
polystyrene plastic in two-dimensional (2D) in vitro system [12-16], although 2D 
cultures impose highly unnatural geometric and mechanical constraints to 
growing cells. Indeed, the most cells reside in vivo in a three-dimensional (3D) 
environment surrounded by ECM and other neighbouring cells, conditions that 
are different from those found by cells cultured in vitro on 2D substrata. As 
consequence, the latter condition fails to provide an accurate representation of in 
vivo growing cells, as they lack the contextual cues found in the native 3D tissue. 
For these reasons, 3D cell cultures are expected to provide a tool bridging the gap 
between the in vitro and the in vivo optimal conditions for cell culture. Thus, 3D 
systems can mirror in vivo conditions more closely than conventional 2D models 
and can be more predictive platforms to assess in vivo delivery efficiencies. In 
this more complex environment, the cellular response to NP diffusion and uptake 
could be so different from what it is expected. Therefore, there is now an 
emerging need to understand how NPs diffuse in the ECM and how cells respond 
to internalized NPs in a more native and complex environment to finally define 
the particle properties which can enhance and optimize their transport/uptake to 
cancer cells. As regarding, the transport of NPs in ECM/tissues depends on the 
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physico-chemical properties of both devices (i.e. shape, size and surface 
chemistry) and ECM [17, 18]. In general, NPs diffuse in ECM network by 
Brownian random walks, and their transport is (indirectly) influenced by steric 
interactions (i.e. collisions with collagen fibers), which depend on NP size, and 
(directly) by the electrostatic interactions between NP surfaces, charged ECM 
components and cells [11]. For these reasons, a major issue in this context is the 
overcoming of the manifold extracellular barriers hampering the reaching of the 
target cells, which are often present within internal regions of tissues. In this 
view, a key concept is to understand how NP size and surface charge influence 
their transport through ECM towards specific cells. Indeed, NP size and surface 
charge are crucial technological features which strongly influence NP 
interactions with the ECM and the cell membranes, and so doing also cellular 
uptake [19-21]. In this way, few studies have been performed to understand how 
cell behaviour and interactions with NPs can change in a 3D environment [22]. 
Other works, instead, are focused on NP diffusion involved in drug delivery 
within dense tumor ECMs that restricted particle penetration. For this issue, the 
most common model was represented by multicellular spheroid [23-25]. For 
instance, Goodman and co-workers studied the effect of polystyrene NPs of 
various sizes (20-40-100 and 200 nm in diameter), combined with collagenase 
treatment, on the uptake by human cervical carcinoma spheroids [26]. The results 
showed that penetration of particles into the spheroid core was limited to NPs 
smaller than 100 nm. However, collagenase-coated 100 nm NPs demonstrated a 
4-fold increase in the number of particles delivered to the spheroid core 
compared to the control NPs, revealing that particles delivery to tumor may be 
substantially imporved by incorporation of ECM-modulating enzymes in the 
delivery formulations. Although the use of spheroids as model of tumor mass 
was helpful, the usefulness of these techniques is limited, due to the spheroid 
structure. Indeed, the spheroids are composed by multicellular layers, made up of 
proliferating cells on the outside, quiescent cells on the inside and necrotic cells 
at the center, due to nutrient and oxygen transport limitations [27]. This complex 
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structure hampers a clear understanding of the mechanisms involved in NP 
internalization by cells. In this panorama, the aim of this work is to understand 
how NP features and 3D environment can affect cellular uptake. In particular, we 
have investigated the influence of particle size and surface functionalization of 
polystyrene (PS) NPs, with two diameters and different surface functionalization 
(-COOH and -NH2 groups), on the transport within collagen and on 
internalization by two cell lines, namely primary human dermal fibroblasts 
(HDF) and human fibrosarcoma (HT1080), entrapped in a 3D collagen matrix, 
using 2D cultures as a reference. The choose of these cell lines underlined the 
need to reproduce the in vitro model of healthy and tumor tissues, HDF and 
HT1080 respectively. On the other hand, the collagen was chosen since is the 
most abundant protein in mammalian organisms and the major component of 
ECM of the connective tissue, which provides tissue mechanical properties [28-
31] and the natural environment for cell growth, adhesion, proliferation, and 
migration [32]. In this work, NP diffusion within collagen matrix and cellular 
uptake kinetics were investigated as a function of NP size and surface charge 
through spectrofluorimetric and confocal microscopy techniques. Moreover, 
starting from experimental data, a mathematical model was developed. The 
model considers NP uptake is envisaged as a process driven by 
adsorption/desorption, followed by NP internalisation via energy-dependent 
pathways. NP internalisation was taken into account starting from a pseudo-
chemical equilibrium, and the numerical simulations were used to 
predict/elucidate the effect of size and surface charge in NP uptake in 3D 
matrices.   
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2.3. MATERIALS AND METHODS 
2.3.1. Polystyrene nanoparticles  
Green dye-loaded (fluorescence: λex ~ 468 nm; λem ~ 508, 0.04 and 0.1 µm, Duke 
Scientific Corporation), yellow-green dye-loaded carboxylate-modified 
microspheres COOH-PS NPs (fluorescence: λex ~ 505 nm; λem ~ 515, 0.1 µm, 
Invitrogen) and orange amine-modified beads NH2-PS NPs (fluorescence: λex ~ 
481 nm; λem ~ 644 nm, 0.1 µm, Sigma Aldrich) were used without further 
modification or purification. NP dispersions were prepared by diluting the 
concentrated stock solutions into the complete medium, Eagle's minimal essential 
medium (EMEM, Lonza) used for cell culture at room temperature (RT) 
immediately prior to the experiments on cells, with an identical time delay 
between diluting and introducing to the cells for all experiments. Before 
sampling, NPs were vigorously mixed by vortexing, as recommended by the 
company. Measurement of size and ζ-potential of NPs were made with ZetaSizer 
Nano ZS (Malvern Instruments, Malvern, UK). 
2.3.2. Three-dimensional collagen matrix 
The collagen solution was purchased from Sigma Aldrich. The collagen gel were 
prepared by diluting stock solution with 10 X Dulbecco’s phosphate saline buffer 
(D-PBS, Gibco) (8:1 volume ratio) and adjusting the pH to 7.2 by dropwise 
addition of NaOH and HCl. The final concentration obtained was 2.4 mg ml
-1
. 
The solution was then poured in right cell culture dish, dependent of kind of 
experiments, and incubated at 37 °C for about 1 h to allow the fibrillogenesis 
process. Afterwards, fresh cell culture medium added to the gel.   
2.3.3. Cell culture  
To test the biological effect of the NPs, Human Dermal Fibroblast (HDF) and 
Human Fibrosarcoma cell lines (HT1080) were used. The latter were cultured 
with complete medium, composed of EMEM supplemented with 10 % fetal 
bovin serum (FBS, Gibco), 100 U/ml penicillin, 100 mg ml
-1
 streptomycin. The 
HDF cell lines were cultured with the same medium but supplemented with 20 % 
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FBS, 100 U/ml penicillin, 100 mg ml
-1 
streptomycin and 2 X non essential 
amino-acids. Cells were incubated in a humidified controlled atmosphere with 95 
% to 5 % ratio of air/CO2, at 37 °C. Medium was changed every 2 days. All 
experiments were performed in triplicate. 
2.3.4. Cell viability and proliferation 
The increment of DNA content was used to estimate cell proliferation within 3D 
collagen matrices. To quantify DNA contents, Pico Green assay (Invitrogen) was 
carried out. After 1, 2, 5 and 7 days of culture, collagen gels were degraded by 
collagenase solution (Roche Applied Science) for about 40 min at 37 °C, at final 
concentration of 2.5 mg ml
-1
. After matrix digestion, cells were recovered by 
centrifugation at 1000 rpm for 5 min and lysated with 0.1 % Triton X 100 
solution in PBS. PicoGreen reagent was added to cell lysates and fluorescence 
was read by a plate reader at 260 nm wavelength. DNA content was evaluated by 
interpolating raw data with the calibration curve. 
2.3.5. Confocal microscopy for nanoparticle uptake in 2D and in 3D systems 
For 2D cell culture conditions, 4 * 10
4
 cells were seeded in 1 ml of medium on 
cover glass. Cells were incubated with all kinds of NPs, at the same 
concentrations used for NP uptake experiments (see below: nanoparticles uptake 
sections), for 24 hours at 37 °C in 5 % CO2. Instead, for the 3D conditions, cells 
were grown in 0.3 ml of collagen at final concentration of 2.4 mg ml
-1
.  The day 
after, samples were rinsed with PBS to remove non internalized NPs and fixed 
with 4 % paraformaldehyde for 20 min under chemical fume hood. Then, cells 
were permeabilized with 0.1 % Triton 100 X in PBS for 10 min and the actin 
microfilament were stained with TRITC-phalloidin (Sigma) for 30 min at RT. 
Cell nuclei were stained with DAPI. Samples were observed by confocal and 
multiphoton microscope system (Leica TCS SP5 MP). Images acquired with a 
resolution of 1024X1024 pixels. 
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2.3.6. Nanoparticle uptake in conventional 2D culture 
To evaluate the intracellular uptake of all kind of NPs, 4 x 10
4
 cells were seeded 
in 1 ml of medium for each cell lines, in 24 well. NPs were dispersed in cell 
culture medium at final concentration of 2.1 * 10
11
 and 1.8 * 10
10
 NP ml
-1
, for 
0.04 and 0.1 µm PS NPs, 1.8 * 10
10
 and 1.83 * 10
10
 NP ml
-1
, for -COOH and -
NH2 PS-NPs, respectively. Cells were incubated with NP suspension for 1, 3, 6, 
9, 15 and 24 hours. After incubation, cells were rinsed two times with PBS and 
lysed with 0.1 ml of buffer composed of 4 % CHAPS, 7 M Urea, 2 M Thiourea 
and 30 nM Trizma, purchased by Sigma Aldrich, and 0.4 ml of PBS. Cell lysates 
were analyzed by a spectrofluorometer (Enspire 2300, Perkin-Elmer), to measure 
the amount of internalized NPs.   
2.3.7. Nanoparticles uptake in 3D collagen matrix 
For the uptake of PS NPs in 3D matrix, 4 x 10
4
 cells were seeded in 0.5 ml of 
collagen in each well of 24 well. After fibrillogenesis, cells were exposed to 4.2 * 
10
11
 and 3.6 * 10
10
 NP ml
-1
 for 0.04 and 0.1 µm PS-NPs, and 3.6 * 10
10
 and 3.66 
* 10
10
, for -COOH and -NH2 PS-NPs, respectively. Cells were incubated with NP 
suspension at the same times reported for NPs uptake in 2D. After each time, the 
collagen gels were digested by collagenase A (see above: cell viability and 
proliferation section). Cell lysates were analyzed by a spectrofluorometer 
(Enspire 2300, Perkin-Elmer).  
2.3.8. Kinetics of nanoparticle uptake 
In this work, NP uptake is viewed as a two-step process consisting of the non-
specific binding (i.e. adsorption) of the NPs onto the cell surface and the 
subsequent cell internalisation. In particular, we consider that cells are initially 
free from NPs and, once at the cell surface, NPs can either be internalised or 
undergo de-binding (i.e. desorption). Therefore, NP uptake can be envisaged as a 
process driven by adsorption/desorption, followed by NP internalisation via 
energy-dependent pathways, and can be modelled by a modified second order 
binding equation, taking into account NP internalisation by a pseudo-chemical 
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equilibrium relation [33], described by the stoichiometric exchange between NPs 
and cell membrane, as follows:  
                   (1) 
Equation (1) describes the overall NP uptake process consisting of NP binding to 
the cell surface followed either by NP de-binding or internalization. Here we 
assume that for each cell population and NP diameter, there exists a limiting 
capacity of binding and another, independent limiting capacity to internalise a 
cell surface on which NPs are attached. The binding capacity is a measure of the 
fraction of the cell membrane able to adsorb NPs (namely the reactive surface) 
[34-36], and was considered constant in time. This means that after each 
internalisation event, the reactive surface is continuously and instantaneously 
regenerated. In particular, the internalisation step occurs by creating an 
intracellular endosome after each NP is internalised.   
Thus, the rate of overall NP uptake is defined by the balance between the rates of 
NP binding/de-binding and of cell internalisation, which are defined by the three 
corresponding kinetic rate coefficients, i.e. kD [mg•mL
-1•h-1], kB [h
-1
] and ki [h
-1
]. 
A modified version of the single cell model of particle interaction was used. The 
following equations describe the interactions of NPs with a single cell in terms of 
the number of particles bound/internalized per cell, and of the total number of 
particles (bound and internalised) as a function of time. The number of NPs 
bound on a cell per unit time is proportional to the concentration of NPs in the 
reservoir (culture medium in 2D or collagen in 3D). De-bound and internalised 
NPs, in turn, are proportional to the number of bound particles. Hence, the 
following equations can be written: 
 
 
ationinternalisNPsurfacecellNPsurfacecellNP iDB
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                                                            (2) 
                                                                                                          (3) 
                                                                                                       (4) 
In each experiment 4 x 104 cells have been used, and 1 mL of culture medium or 
collagen employed. Under these conditions, experimental results showed that the 
 term could not be considered constant in all cases, due to extensive NP 
uptake. Therefore, in model equations the time variation of NP concentration 
within the culture medium, i.e. an important driving force of the process, was 
taken into account. In particular, NP concentration within the culture medium 
was modeled considering that the rate of NP disappearance in the culture 
medium was the opposite of the rate of the overall uptaken NPs (i.e. ). 
                                                            (5) 
2.3.9. Scanning Electron Microscopy (SEM) 
After 24 hours of incubation, with all type of PS-NPs at the same concentrations 
used for uptake experiments, 3D collagen matrix was rinsed two times with PBS 
and fixed with 2.5 % glutaraldehyde + 0.1 M cacodylate for 3 hours and 
dehydrated in increasing ethanol series (70 %, 80 %, 90 % and 100 %), then the 
samples were submitted for critical point (LEICA EM CPD300). The samples 
were platinum/palladium–sputtered and analyzed by SEM (Leica S400). 
2.3.10. PS-NPs diffusion in collagen matrix  
Permeability experiments of NPs were performed using transwell permeable 
inserts (6.5 mm in diameter, 3 μm pores size; Corning Incorporated, Corning, 
NY). The times of kinetics were the same used for NP uptake. For 2D 
experiments, 0.1 ml of cell culture medium w/o phenol red containing the right 
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NP concentrations were added to donor chamber; while the acceptor chamber 
was filled with 0.4 ml fresh cell culture medium. For 3D experiments, the 
medium with NPs were added after collagen fibrillation. After each time, the 
donor chamber was shifted to new acceptor chamber with the same amount of 
fresh medium. The fluorescence tracer concentration in the samples was 
determined by a spectrophotometric analysis (Enspire 2300, Perkin-Elmer). The 
results were reported as percentage of transported NPs. 
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2.4. RESULTS AND DISCUSSION 
2.4.1. Cell viability and proliferation 
To assess cell viability and proliferation within 3D collagen matrix, Pico Green 
assay was carried out (Fig. 1A). The equal number of cancer and non-cancer 
cells was embedded and grown within the matrix until one week. It was observed 
that, for both cell lines, the proliferation rate was not in any way hindered in our 
3D environment. Conversely, the cells were grown in optimal condition for all 
biological activities, such as in traditional 2D cell culture. In particular, the HDF 
proliferation rate was slower compared to HT1080 proliferation rate already from 
24 hours in both conditions.  
 
Figure 5. Cell behaviour and morphology in 3D collagen matrix. A) Proliferation rate of HDF 
and HT1080 cell lines followed for 7 days, in 3D collagen matrix obtained by DNA 
quantification (PicoGreen assay); Optical microscope images of HT1080 cells after 24 h of 
growth in 2D culture dish (B) and 3D collagen matrix (C). Objective 10X. 
Indeed, the cancer cells were distinguished from normal cells by abnormal 
activities, such as unlimited replication, proliferation and reproducing follow by 
tissue invasion and related metastasis, sustained angiogenesis, insensitivity to 
antigrowth signals [37, 38]. Furthermore, it is important to underline that cell 
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morphology changed when cells were grown in a more natural environment. In 
particular, HT1080 adopted more rounded shaped within collagen matrix 
compared to flat morphology typical of conventional systems (Fig. 1B-C). This 
change in cell morphology can reflect a different cytoskeleton organization 
between 2D and 3D systems [39, 40]. 
2.4.2. Nanoparticle characterization 
Fluorescently PS-NPs were dispersed in phosphate buffer saline in order to 
determine nanoparticle size, polydispersivity and ζ-potential by dynamic light 
scattering (DLS). The DLS measurements showed that PS-NPs had a good 
stability and monodispersion in PBS solution, while the ζ-potential reflected the 
positive surface charge related to the presence of amine groups, and the negative 
charge due to the carboxyl groups (Table 1). All properties of PS-NPs, measured 
by DLS analysis, were consistent with their theoretical features.   
 
Table 1. Measurements of size and ζ-potential of all PS-NPs by dynamic light scattering. 
 
2.4.3. Nanoparticles uptake 
To investigate NPs internalization, HDF and HT1080 cell lines were exposed to 
all PS-NPs in both 2D and 3D culture conditions. The confocal images of 
HT1080 cells, in traditional 2D system, showed that NPs entered the cells and 
their number increased in time, as indicated by fluorescence intensity 
enhancement (Fig. 2).  
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Figure 2. Confocal image of HT1080 cells incubated at 37 °C with 44-NPs for 1 h (a), 6 h (b) 
and 24 h (c). Different colors are applied to improve visualization: nuclei (DAPI) are shown in 
blue; actin filaments (phalloidin) in red; nanoparticles in green. Scale bar: 10 µm. 
In addition, as shown in Fig. 3, all PS-NPs were efficiently internalized by 
cancer cells after 24 hours of incubation.  
 
Figure 3. Confocal image of HT1080 cells incubated for 24 h with 44-NPs (a), 100-NPs (b), 
COOH-NPs (c) and NH2-NPs. Different colors are applied to improve visualization: nuclei 
(DAPI) are shown in blue; actin filaments (phalloidin) in red; nanoparticles in green. Scale 
bar: 10 µm. 
On the other hand, confocal images of HDF cell line also confirmed the presence 
of all kind of particles, used in this work, within fibroblats after 24 hours of 
incubation (Fig. 4).   
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Figure 4. Confocal image of HDF cells incubated for 24 h with 44-NPs (a), 100-NPs (b), 
COOH-NPs (c) and NH2-NPs. Different colors are applied to improve visualization: nuclei 
(DAPI) are shown in blue; actin filaments (phalloidin) in red; nanoparticles in green. Scale 
bar: 10 µm. 
Moreover, apparently the amount of PS-NPs internalized by cells seems to be 
higher for HT1080 compared to healthy cells, probably due to a different 
cytoskeletal organization between cancer and non cancer cells (Fig. 5). Indeed, 
Swartz et al demonstrated that a malignant phenotype of HT1080 cells induced 
profound change in cytoskeleton structure, including rounding shape and diffuse 
myosin expression [40].  
 
Figure 5. Confocal images of HT180 cells (a) and HDF cells (b) after 24 hours of incubation 
with 100-NPs. Different colors are applied to improve visualization: nuclei (DAPI) are shown 
in blue; actin filaments (phalloidin) in red; nanoparticles in green. Scale bar: 10 µm. 
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Noteworthy, in both cell types the NPs were distributed in the cytoplasm, mainly 
localized around the nucleus. Also, the confocal z-sectioning of HT1080 cells 
embedded in 3D collagen matrix confirmed the NP distribution observed for 
confocal images acquired in 2D cell culture conditions (Fig. 6).  Apparently, 
uptaken NPs by cells were higher for 2D compared to 3D matrix, as shown in 
Fig. 6 with the compressed z-stack as the central image and projection through 
the z-plane along the red line in the x- and y- directions given as the sidebars. 
These qualitative results were confirmed by quantification of uptaken NPs, 
exploiting dye-loaded inside the particles, through spectrophotometric analysis. 
The amount of internalized NPs was quantified on a number of NPs per cell 
basis. In the framework of this work, NP uptake is considered to be governed by 
the balance between NP adhesion to the external cell membrane and NP actual 
internalization [34]. In particular, during the initial transient state, NPs adhere to 
the cells, but the process of internalization is still slow. At the pseudo-steady 
state, the number of NPs bound to the cell surface equals the number of NPs 
being internalised, which is consistent with a linear uptake. This view suggests 
that NP uptake is predominantly determined by NP binding/adsorption to the 
external cell membrane. The adhesion properties of NPs to the cell membrane are 
difficult to distinguish when internalisation events are simultaneously occurring. 
Indeed, NP binding to cell membrane is normally quantified by incubating the 
cells with NP at 4 °C, so as to inhibit internalisation phenomena and estimate the 
number of particles adsorbed [34, 41-43]. However, this is cumbersome to carry 
out in a 3D system. Furthermore, for prolonged times of incubation, in some 
papers desorption phenomena were observed, and this makes the distinction 
between adsorbed and internalised NPs unreliable and probably meaningless in 
the experimental conditions used in this work. 
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Figure 6. Confocal z-sectioning images of HT1080 cells incubated with a) 44-NPs b) 100-NPs 
c) NH2-NPs d) COOH-NPs in 3D collagen matrix for 24 hours. Nuclei: blue; TRITC: 
phalloidin; Green: NPs; Transmission: collagen. Obj 63 X oil. Magnification bar: 10 µm. 
Therefore, the uptake experiments were all performed at 37 °C without 
discriminating between bound and internalized NPs. The uptake kinetics of PS-
NPs, COOH-NPs and NH2-NPs by HDF and HT1080 cells, together with the 
results of numerical simulations, are shown in Figs. 7 and 8. Under all culture 
conditions, and for each NP type and size, the uptake kinetics exhibited a 
qualitatively similar behaviour with an initial faster transient followed by a sort 
of quasi-linear uptake in the experimental time frame of this work (48 h). As for 
PS NPs, results showed that the uptake was higher in the case of HT1080 cells 
compared to HDF cells. The number of uptaken NPs was shown to depend on 
particle size, surface functionalization and culture model and, in all cases, was 
steadily increased with time and, specifically, higher for 44 nm NPs than for 100 
nm. The uptake saturation was not reached within 48 h, and this was the most 
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evident in the case of HDF cells cultured with 44 nm NPs. Highest levels of 
uptake were observed for 44 nm, in 2D conditions and for HT1080 cells. In 
particular, size effect was found out to be mostly predominant for three 
dimensional collagen scaffolds in whose twisted network NPs with small 
diameter diffused much better than bigger ones. In fact, increasing NP size, a 
slight decrease of NPs internalized was observed.  
 
Figure 7. Kinetics of uptake of fluorescently labeled 44 and 100 nm NPs by HDF (A, B) and 
HT1080 cells (C, D) during continuous exposure, as determined by spectrophotometric analysis 
Cells were exposed to NPs in both 2D [2.1*10
11
 and 1.8*10
10 
for 44 and 100-NPs, respectively] 
and 3D conditions [4.2*10
11
 and 3.6*10
10
 for 44 and 100-NPs, respectively]. The mean cell 
fluorescence of 4 x 10
4
 cells was determined for each repeat. Data points and error bars 
represent the mean and standard deviation over three replicas. The solid lines represent results 
obtained by data fitting. 
Furthermore, for prolonged times of incubation, we have also observed 
desorption phenomena, which also contributes to the meaninglessness of the 
discrimination between adsorbed and internalised NPs. The lower uptake in 3D 
can be easily related to the tight contact established between NPs and collagen 
fibers, which occurs during diffusion in 3D complex, before NPs reach cells. 
Indeed, all other conditions being equal, the 48 h uptake of 44 nm NPs was 13-16 
times higher compared to the uptake of 100 nm NPs. However, it should be taken 
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into account that the uptake of NPs did not reach a plateau in the timeframe of 
cell culture used in this work. The values of NMAX, calculated by fitting uptake 
kinetics data to equations (1)-(4), suggest that the uptake of 44 nm PS NPs after 
an infinite time is from 6 to 166 times higher compared to NMAX of 100 nm NPs 
(Table 2). Therefore, the number of uptaken NPs increased significantly with 
decreasing particle size for both cell lines on both culture conditions, i.e. the cells 
have a higher uptake capacity for the smaller particles. Overall, PS NP uptake 
was lower on 3D versus 2D substrates as shown in Fig. 7 and 8. For both NP 
sizes the uptake was 3- and 4- fold higher for HDF and HT1080 cells, 
respectively. A similar comparison on NMAX shows that the decrease in uptake of 
NPs in 3D versus 2D culture conditions is mainly influenced smaller NP size and 
for HT1080 rather than HDF cells. The rate coefficients for binding (KB), de-
binding (KD) and internalisation (Ki) versus size/cell line and culture conditions 
(2D and 3D) are summarised in Table 2.  
 
Figura 8. Kinetics of uptake of fluorescently labeled 100 nm COOH-NPs and 100 nm NH2-NPs 
by HDF (A-C) and HT1080 cells (B-C) during continuous exposure, as determined by 
spectrophotometric analysis. Cells were exposed to NPs in both 2D [1.8*10
10
 and 1.83*10
10
 for 
COOH and NH2-NPs, respectively] and 3D conditions [3.6*10
10
 and 3.66*10
10 
for COOH and 
NH2-NPs]. The mean cell fluorescence of 4 x 10
4
 cells was determined for each repeat. Data 
points and error bars represent the mean and standard deviation over three replicas. The solid 
lines represent results obtained by data fitting. 
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The adsorption rate coefficient, KB is higher for the 2D culture system in the case 
of 100 nm NPs, while it is higher for the 3D culture for 44 nm diameter particles, 
which have a 2.1-4.8 fold change for 3D over 2D as for HDF and HT1080 cells, 
respectively. In the case of 100 nm NPs, KB is 1.8 and 2.6-fold higher for 2D 
versus 3D-grown HDF/HT1080 cells. The other rate coefficients randomly vary 
with NP size, culture conditions and cell line. The COOH-NPs showed a 
drastically lower uptake compared to the PS-NP, in both cell culture conditions 
(Fig. 8). In particular, we found that the uptake in 2D was 5-6 fold less than in 
2D and about 2-2.5 times lower in 3D. When passing from 2D to 3D, however, 
there was a slighter uptake reduction compared to what happened when using 
PS-NPs. Conversely, NH2-NPs displayed a peculiar behavior: indeed, in 2D the 
uptake was only slightly lower in the case of HDF cells, while being basically the 
same for HT1080 cells. Surprisingly, in 3D a strong increase in uptake was found 
out. In particular, depending on the cells population, NP increase of NH2-NPs 
was 2-4 fold higher compared to bare PS-NPs (Fig. 8). 
 
Table 2. Model parameters of 44-NPs and 100 NPs (a); COOH-NPs (b); NH2-NPs.  
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2.4.4. PS-NPs diffusion in collagen matrix and scanning electron microscopy  
The cellular uptake results obtained regarding anionic particles in 3D matrix 
suggested the existence of possible interactions among several collagen 
components and carboxyl groups upon the surface of the negative NPs. Indeed, 
images acquired by scanning electron microscopy showed that COOH-NPs 
interacted with collagen fibers, generating cluster structures as shown in Fig. 9E. 
Conversely, NH2-NPs slipped among the network of fibers without absorbing on 
their surfaces (Fig. 9D). Furthermore, only few nanoparticles of 44 and 100 nm 
interacted with fibers (Fig. 9B-C).  
 
Figure 9. Scanning electron microscopy images of all PS-NPs in 3D collagen matrix after 24 
hours of incubation. A) Collagen without PS-NPs, used as control; B) with 44 nm PS-NPs; C) 
with 100 nm PS-NPs; D) with 100 nm NH2-NPs; E) with 100 nm COOH-NPs. Bare scale: 0.2 
µm. 
Hence, for better understanding NP behaviour in collagen matrices, permeability 
experiments using transwell permeable insert were performed. This system is 
composed by a donor and acceptor chamber separated by a membrane pore filter 
and has allowed to study NP diffusion crossing collagen gel. The same 
experiments are followed in transwell without collagen scaffold to rule out that 
membrane pore filter could hinder NP diffusion (data not shown). Results were 
expressed as percentage of NP transported in function of time. Data showed that 
the smaller particles diffused without any apparent hindrance in the collagen 
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matrix, as shown also in Fig. 10, where reached a plateau already to 6 hours. The 
same results were registered for cationic NPs in which the total amount of NPs 
crossed the scaffold in few hours. Conversely, the percentage of COOH-NPs that 
passed through the 3D matrix in 24 hours was very low, since just the 27 % was 
measured in the acceptor chamber. These results suggested the possibility of 
interactions between negative NPs and collagen fibers that could hinder the NP 
ability to diffuse within matrix (Fig. 7). As regarding, the neutral 100-NPs 
showed an intermediate behaviour, where the total amount of NPs that crossing 
the matrix run out within 15 hours.   
 
Figure 10. Diffusion study of PS-NPs using transwell permeable inserts until 24 hours. 
Taken all together, these results demonstrated that surface features, due to the 
charge of NPs in contact with ECM components, play a crucial role on their 
diffusion in 3D matrix and consequently in cellular uptake. Indeed, we showed 
that a large amount of anionic NPs interacted with ECM components and 
remained attached on the surface of collagen fibers. This effect could suggest 
that, in our experimental conditions, collagen gel could take a slight positive 
charge, generating attractive electrostatic interactions with the COOH-NPs. 
Nevertheless, further investigations are necessary to clarify which relationships 
are established among ECM molecules and surface of charged NPs. 
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2.5. CONCLUSIONS 
Three-dimensional gel matrices provide the opportunity to reproduce natural 
microenvironments that mimic the native tissues where essential cell activities 
are regulated, such as proliferation, adhesion and differentiation. In this more 
complex framework, also cellular responses to particles, in term of NP uptake 
could drastically change. This point is of extreme relevance, in particular for 
biomedical fields, since also NP properties can influence their diffusion in 3D 
environment and to generate cellular response quite different from that expected. 
In this work, we demonstrated that all NP properties are crucial to crossing the 
matrix. First, NP diameter showed to be a crucial parameter in fact 44-NPs 
diffused better in 3D matrix and consequently their cellular uptake was massive. 
Importantly, the amount of NPs observed within cancer cells was higher 
compared to healthy cells. This effect can be attributed to a different cytoskeleton 
organization between cancer and non-cancer cells. Swartz et al demonstrated that 
a malignant phenotype of HT1080 cells induces profound change in cytoskeleton 
structure, including pronounced rounding and diffuse myosin expression also in 
3D system [40]. Moreover, recent data suggested that myosin VI plays a role in 
clathrin-coated vesicle formation and the trafficking of uncoated nascent 
vesicles. It is likely that in both processes, myosin VI plays an accessory role, 
perhaps increasing the efficiency of endocytosis [44]. In agreement with our 
results, these data could explain the greater NP uptake in tumor cells. In addition, 
increasing NP size a decrement of uptaken NPs was detected in both 2D and 3D 
conditions. The results can be attributed not only at the bigger size, but mainly to 
the surface charge of NPs. Indeed, the surface functionalization of nanoparticles 
is crucial for the durability, suspensibility in biological media, biocompability 
and biodistribution [45, 46]. We demonstrated that positive charge on surface of 
NPs allowed them to be internalized into cells in greater numbers compared to 
negative one, in both 2D and 3D systems. This effect was mainly due to the 
positive charge that improves their diffusion in collagen matrix and increases the 
cell surface affinity and uptake in both cell lines. This phenomenon may be 
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caused by electrostatic interactions with the net negative surface charge of 
plasma membrane that favour NH2-NP uptake [47, 48]. In addition, 
independently from NP size or surface charge, their uptake in both cell lines was 
lower in 3D collagen matrix compared to 2D cell culture systems. The reasons to 
explain this behaviour can be manifolds. First, the path that particles must follow 
to reach cells in a three-dimensional matrix is longer compared to that observed 
in 2D systems. Indeed, the cell arrangement on monolayers makes them most 
available for NP uptake. Second, cell morphology in 3D condition was 
drastically changed compared to 2D system, in particular way for HT1080 cell 
line that adopted a shape relatively more rounded in collagen matrix [40]. 
Furthermore, the difference in cell morphology reflected the different 
cytoskeletal organization within cells, as observed in previous works with other 
cells grown in 3D matrix. Indeed, some studies demonstrated that the 
organization of actin’ microfilaments and stability of microtubules was 
drastically different compared to 2D system [49, 50]. These distinct 
organizations could influence not only cellular activity, such as mobility and 
migration, but also the amount of NPs that cells are able to internalize. In this 
view, further investigations are necessary to define if the molecular expression of 
several proteins involved in active endocytosis mechanisms could be altered 
when moving to three-dimensional systems. 
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CHAPTER 3 
 
In vitro release features and cytotoxicity assays in 2D and 3D cell 
culture of sub-100 nm PELGA nanoparticles loaded with 
doxorubicin 
 
 
3.1. ABSTRACT 
A big challenge in tumor targeting by nanoparticles (NPs), taking advantage of 
the enhanced permeability and retention effect, is the fabrication of small size 
carriers for enhanced diffusion and penetration in tumor, which is considered 
fundamental to improve chemotherapy efficacy. The purposes of this study are 
(i) to prepare the formulation of doxorubicin-loaded poly(D,L-lactic-co-glycolic 
acid) (PLGA)–block–poly(ethylene glycol) (PEG) NPs to obtain <100 nm 
carriers, and (ii) to translate standard 2D cytotoxicity studies to 3D collagen 
systems in which an initial step gradient of the NPs is present. Indeed, the study 
of NP mediated drug delivery in a 3D in vitro model would resemble a more 
realistic estimate of drug efficiency before the in vivo tests. The release of 
doxorubicin can be prolonged for days to weeks depending on the NP 
formulation and the pH of the release medium. Moreover, Dox-loaded PELGA 
NPs were characterized for size distribution, ζ –potential and release kinetics at 
the pH physiological milieu, of the tumor ECM and lysosomes. The effect of the 
formulation on the uptake and cytotoxicity was investigated in HeLa and 
IGROV-1 cells, which are used as in vitro models of human cervix carcinoma 
and ovarian adenocarcinoma, respectively. The results showed that smaller NPs 
than 100 nm are effectively internalized by HeLa cells in 2D and are less 
cytotoxic compared to free doxorubicin. In 3D, < 100 nm NPs are significantly 
more toxic than larger ones towards HeLa cells, and the cell death rate is affected 
by the contributions of drug release and device transport through collagen. Thus, 
the reduction of NP size is a fundamental feature from both a technological and a 
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biological point of view and must be properly engineered to optimize the tumor 
response to the NPs. 
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3.2. INTRODUCTION 
Nanoparticles (NPs) have received great attention as carriers in cancer therapy 
since nanocarrier-mediated drug delivery (i) enhances the antitumor efficacy of 
many chemotherapeutic drugs, (ii) helps to reduce unwanted drug-related side 
effects, and (iii) limits the effects of multi-drug resistance (MDR) by evading 
drug efflux pumps, whereas intracellular drug concentration can be increased [1-
3]. Furthermore, NPs can guide the drug preferentially to tumor cells and tissues 
by taking advantage of NP active and/or passive targeting [4-7]. Passive targeting 
generally refers to the well-known enhanced permeability and retention (EPR) 
effect [8-11], which is promoted when NPs possess a hydrophilic surface, a 
quasi-neutral ζ-potential [12] and a controlled size of approximately 70–200 nm 
[13-16]. In particular, size reduction positively affects carrier extravasation, 
penetration depth and cell uptake [17, 18], depending on the properties of both 
the biological environment (density, distribution, aggregation and size of 
vascular fenestrae) and the NPs (shape and surface charge) [10, 17-22]. 
The efficacy of anticancer drugs and NPs is often tested in 2D cell cultures, but 
drug efficacy in vivo is generally lower, and this difference is partly due to the 
3D nature of tumor tissue. In fact, cells grown in 3D have totally different 
behaviors, in terms of cell surface receptor expression and proliferation [23, 24], 
extracellular matrix (ECM) synthesis [25] and metabolic functions [26]. This 
discrepancy has been suggested to depend on the loss of key regulators and tissue 
phenotypes in 2D cell cultures [27]. Indeed, the study of NP-mediated drug 
delivery in a 3D in vitro model would simulate a more realistic estimate of drug 
efficacy before in vivo tests. To date, systematic studies dealing with the effect of 
NP size on cell uptake and cytotoxicity have been carried out basically with 
model NPs with diameters ranging from tens to several hundreds of nm [28, 29]. 
Few attempts have been made to develop in vitro 3D models to evaluate the 
efficacy of anticancer drugs [30, 31], which are particularly relevant because in 
3D cells ‘sense’ the ECM all around, thus producing phenotypic differences and 
modifying their behavior accordingly [32-34]. 
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In this framework, the aim of this study was to produce small sized (sub-100 nm) 
NPs made up of a biodegradable poly(D,L-lactic-co-glycolic acid) (PLGA)–
block–poly(ethylene glycol) (PEG) copolymer (namely PELGA), which holds 
promise for accumulation in hypervascular tumors [15], and compare the effect 
of the formulation on cell uptake and cytotoxicity. PELGA copolymer was 
synthesized in our laboratories and chosen as the NP-constituting amphiphilic 
copolymer since both PEG and PLGA meet FDA approval criteria for clinical 
use as drug adjuvants. As a proof-of concept study, we report on the production 
and technological characterization of PELGA NPs, loaded with a 
chemotherapeutic agent called doxorubicin (Dox), in terms of technological 
features, cell uptake and cytotoxicity behavior as a function of the formulation. 
Dox is an anthracycline which exerts its cytotoxic effect by intercalating the 
planar aromatic chromophore portion between two base pairs of DNA [35, 36], 
thus inhibiting the progression of the enzyme topoisomerase II and hence the 
synthesis of nucleic acids within cells [37, 38]. When intravenously 
administered, Dox lacks specificity towards tumor tissues [39] and causes severe 
side effects such as myelosuppression, irreversible cardiotoxicity [40] and 
nephrotoxicity [41]. Thus, many studies have focused on the development of 
drug delivery systems and administration routes for Dox to increase tissue 
selectivity and improve its toxicity profile [42-44]. Indeed, free and polymer-
conjugated Dox has been successfully loaded into many nanometric devices, 
including NPs [45] and liposomes [46]. Dox release from nanodevices can 
reduce drug-associated toxic side effects and metastasis generation in murine 
models [47, 48], possibly due to drug transfer to the malignant tissues from 
hepatic tissue, acting as a drug reservoir [49]. Some clinical success has also 
been attained by nanocarrier-mediated Dox release. Indeed, drug toxicity towards 
the heart and liver could be reduced, probably due to a lower cumulative dose 
(around 180 mg m
-2
), with a degree of success depending on tumor localization 
with respect to the liver, which probably governs the attainment of therapeutic 
drug concentrations in target tissues [50]. Dox is widely used in cancer 
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chemotherapy, either as a single agent or in combination with other 
chemotherapeutics [51, 52], and in this work was chosen as a model molecule for 
NP loading [35, 53]. PELGA NPs were prepared by the double emulsion–solvent 
diffusion technique, which allows the encapsulation of hydrophilic molecules 
within a compartmentalized structure together with a controlled drug release 
kinetics [54, 55]. Dox-loaded PELGA NPs were characterized for size 
distribution, ζ-potential and release kinetics at the pH of the physiological 
environment, of the tumor ECM and of lysosomes (7.4, 6.8 and 5.0, 
respectively). The effect of the formulation on the uptake and cytotoxicity was 
investigated in standard two-dimensional (2D) cell cultures on HeLa and 
IGROV-1 cells, which were used as in vitro models of human cervix carcinoma 
and ovarian adenocarcinoma, respectively. The cytotoxicity of Dox-loaded 
PELGA NPs towards HeLa cells was also assessed in three-dimensional (3D) 
collagen matrices, in which the NPs were confined in a region separated from the 
cells by a porous membrane, thus creating an initial step gradient of the Dox. The 
cytotoxicity of the Dox/NPs was quantified by time-lapse monitoring of Dox 
accumulation in cell nuclei at different distances from the deposition site and as a 
function of NP formulation/size. 
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3.3. MATERIALS AND METHODS 
3.3.1. Materials 
Equimolar uncapped Poly (D,L-lactide-co-glycolide) (PLGA) (Resomer 
RG502H, Mw 12 000 Da, inherent viscosity 0:16–0:24 dl g-1 in chloroform at 
25° C) was purchased from Boehringer Ingelheim (Ingelheim, Germany). 
Doxorubicin hydrochloride (Dox; purity >99%) was obtained from Discovery 
Fine Chemicals (Wimborne, UK). Type one collagen solution from bovine skin, 
potassium bromide, pluronic F68, dicyclohexylcarbodiimide (DCC), 4-
(dimethylamino)pyridine (DMAP), dichloromethane (DCM), ethyl acetate (EA), 
sodium dihydrogen phosphate, disodium hydrogen phosphate, trehalose 
dihydrate and polyethylene glycol (PEG, Mw 1500 Da), rhodamine B (Rhod), 1- 
ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC-HCl), 
ethyldiisopropylamine (EDPA) and dimethylformamide (DMF) were obtained 
from Sigma-Aldrich (USA). Analytical grade dimethyl sulfoxide (DMSO) was 
purchased from J T Baker (The Netherlands). Bidistilled water was pretreated 
with a Milli-Q R Plus System (Millipore Corporation, Bedford, USA). Phosphate 
buffer saline (PBS) tablets without calcium and magnesium were obtained from 
MP Biomedicals Inc. (France). Dulbecco’s modified Eagle’s Medium (DMEM) 
and 10X Dulbecco’s phosphate saline buffer from Gibco R, Life Technologies 
and containing 1 g
-1
 glucose were purchased from Invitrogen. Fetal bovine serum 
(FBS), penicillin and streptomycin from HyClone (UK) and RPMI 1640 medium 
(Lonza, Switzerland) were used. 
3.3.2. Synthesis of PLGA–PEG copolymer 
PLGA–PEG (PELGA) copolymer was synthesized via a coupling reaction 
between PLGA and PEG similarly to a previously reported procedure [57]. The 
reaction scheme is reported in Fig. 1(A). Briefly, 2.4 g of PLGA 502H, 1.2 g of 
PEG, 0.165 g of DCC (0.8 mmol) and 0.049 g of DMAP (0.8 mmol) were 
dissolved in 20 ml of anhydrous DCM. The reaction was carried out at room 
temperature for 2 days under an inert nitrogen atmosphere. Afterwards, the 
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residual DCC was changed into dicyclohexylcarbodiurea (DCU) by adding 10 µl 
of bidistilled water and the DCU was removed by filtration as a reaction 
byproduct. Unreacted PEG was separated by precipitation five times in methanol, 
while unreacted PLGA was removed by precipitation in ethyl ether. Both 
protocols were performed five times at 4 °C. Finally, the residue was dried 
overnight under vacuum at room temperature. 
 
Figure 1. Synthesis and characterization of the poly(d,l-lactic-co-glycolic acid) (PLGA) – block 
– poly(ethylene glycol) (PEG) (PELGA) copolymer. A: Synthetic reaction scheme of the PLGA-
PEG reaction. FITR spectra of the reactants (PEG, PLGA) and of the product (PELGA). 
3.3.3. Synthesis of PLGA–rhodamine copolymer 
For uptake and colocalization experiments, fluorescent NPs were prepared by 
conjugating Rhod to PLGA. The polymer (3 g) was reacted with Rhod in the 
presence of EDC-HCl and EDPA in 5 ml anhydrous DCM under nitrogen 
atmosphere. The reacting mixture was stirred at room temperature for one day. 
Afterwards, aminated PLGA (0.2 g) was conjugated to Rhod (38.4 mg) with 
EDC-HCl (15.5 mg) and EDPA (10.4 mg) in 1 ml anhydrous DMF. The reacting 
mixture was stirred for 24 h at room temperature, protected from light, under 
nitrogen atmosphere. The polymer was precipitated in water solution and filtered. 
The resulting solid material was dissolved with DCM, and the polymeric solution 
was washed with water three times. Afterwards, DCM solution was poured into 
anhydrous sodium sulfate, set under agitation overnight, and finally precipitated 
and washed with methanol as described in section 2.2. Rhod-PLGA was used to 
prepare fluorescent NPs for uptake and colocalization studies, and unreacted 
Rhod was removed by dialysis against water.  
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3.3.4. Fourier transform infrared (FTIR) analysis 
Fourier transform infrared spectroscopy (FTIR) spectra of the PELGA copolymer 
were recorded using a Nicolet 6700, Thermo Fisher Scientific Inc. (USA) 
spectrometer with an average of 50 scans. The samples were crushed with 
potassium bromide and the spectra of PLGA, PEG and PELGA were scanned in 
the 4000–400 cm-1 range. 
3.3.5. Nanoparticle preparation and characterization 
Blank and Dox-loaded NPs were prepared by a modified double emulsion–
solvent diffusion technique. Briefly, the internal aqueous phase, composed of 0.5 
ml of ultrapure water or of a 4 mg ml
-1
 Dox aqueous solution, was emulsified by 
vortexing for 5 min with 5 ml of 10 or 20 mg ml
-1 
PEG–PLGA solution in EA. 
The NP formulations were named PELGA10 and PELGA 20, respectively, and 
the drug:polymer mass ratios were 1:25 and 1:50. The resulting emulsion was 
sonicated for 30 s (output power: 50 W) over an ice bath with a probe sonifier 
(Branson S250-D, USA). The primary nanoemulsion was immediately poured 
into 15 ml of 1% (w/v) aqueous Pluronic F68 and further sonicated (120 s, 75 
W). The resulting double emulsion was then poured into 35 ml of water and 
stirred overnight for complete diffusion and evaporation of EA. Furthermore, to 
examine the effect of device size on cell internalization, NPs with larger 
diameters (>100 nm) were produced using a 40 mg ml
-1
 solution of PELGA in 
EA as the organic phase; the second sonication was carried out at 50 W for 30 s. 
This formulation was named PELGA40. The NP suspensions were centrifuged 
(AvantiTM J-25, Beckman, USA) for 30 min (4 C, 24 000 rpm) and ultrafiltered 
twice using an ultrafiltration concentrator (MWCO 10 000 Da, Corning) for 15 
min (4, 5000 rpm) for washing. Subsequently, the NPs were resuspended in 1.5 
ml of aqueous 5% w/v trehalose as a cryoprotectant, and lyophilized (Heto 
PowerDry PL6000 Freeze Dryer, Thermo Electron Corp., USA; -50 °C, 0.73 
hPa) for 24 h. NP morphology was investigated through a transmission electron 
microscope (TEM EM208S, Philips, The Netherlands) by spraying 5 ml of 
ultradiluted NP suspension in ultrapure water onto a copper TEM grid (300 
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meshes, 3 mm diameter). NP mean size, size distribution and  -potential were 
determined by laser light scattering (ZetaSizer Nano ZS, Malvern Instruments, 
Malvern, UK) on a 0.1 mg ml
-1
 suspension of NPs in water (12 runs each 
sample). NP size and size distribution were also determined after 24 h incubation 
in cell culture medium to assess device stability during the time frame of the cell 
uptake/cytotoxicity experiments. Results were averaged on at least five 
measurements. Prior to the cell experiments, NP stability in cell culture medium 
was investigated to assess whether the NPs aggregated in the time frame of the 
cell uptake tests. Stability tests were performed by incubating 100 µl of NP 
suspension in 1 ml of cell culture medium at 37 °C for 24 h, and by determining 
size distributions at time zero and after 24 h. Size measurements were also 
performed on cell culture medium at time zero and after 24 h to verify its 
possible self-aggregation. Dox entrapment efficiency was calculated by 
dissolving freeze-dried NPs (1 mg) in 1 ml of DCM. The solvent was evaporated 
at room temperature for 6 h and, subsequently, 1 ml of dimethyl sulfoxide 
(DMSO) was added to dissolve the Dox. The resulting solution was sonicated 
(FALC, Italy) for 1 h in a water bath at 59 kHz, 100 % power and filtered by a 
0.45 µm polyvinylidene fluoride (PVDF) membrane filter (Millipore Filter 
Corporation, Bedford, MA). Dox content was quantified by spectrofluorimetric 
assay (Wallac 1420 Victor2TM, Perkin-Elmer, USA) at 488 nm, performed in 
96-well black flat-bottom plates (Corning, USA). The linearity of the 
spectrofluorimeter response was verified on Dox solutions in DMSO (0.1–10 µg 
ml
-1
 concentration range; r
2
 > 0.99). Entrapped Dox percentage was calculated as 
η 100 * Dox entrapped/Dox total. Results were averaged on three batches. For 
uptake/colocalization experiments, Dox-free fluorescent NPs were produced by 
dissolving Rhod–PLGA and PELGA (1:1 weight ratio) in the organic phase of 
the emulsion (10% w/v). The produced formulation was named Rhod–
PELGA10, correspondingly.  
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3.3.6. Thermal analyses 
To assess the influence of the synthesis and the formulation parameter on the 
thermal properties of both materials and devices, thermograms reporting glass 
transition temperatures (Tg) and/or melting point temperatures (Tm) of the raw 
polymers (PEG, PLGA, PELGA), as well as Dox, placebo and 
PELGA10/PELGA20 Dox-loaded NPs were acquired by a differential scanning 
calorimeter (DSC Q20, TA Instruments) calibrated with a pure indium standard 
and operating under an inert nitrogen atmosphere (flow rate: 50 ml min
-1
). 
Desiccated samples (mass: 2–5 mg) were placed in aluminium pans, and an 
empty one was used as a reference. The determination was made by cooling the 
sample from room temperature to -40 °C and then heating to 250 °C (0 and 200 
°C for PLGA) at a heating rate of 5 °C min
-1
 for all runs. In the case of Dox, the 
samples were heated from room temperature to 250 °C. The thermograms were 
obtained after the second heating of the samples. Results were averaged on at 
least three repeats. 
3.3.7. In vitro release kinetics of doxorubicin 
Dox release kinetics from PELGA10 and PELGA20 NPs were evaluated by a 
standard sampling-separation method in PBS at pH 7.4, or in phosphate buffers 
(PBS) at pH 6.8 and pH 5.0. The buffers were prepared by mixing 0.5 M sodium 
dihydrogen phosphate and 0.5 M disodium hydrogen phosphate aqueous 
solutions. For release experiments, dialysis bags (MWCO 10 000 Da, Spectra) 
were loaded with 1 ml of NP suspensions (1 mg ml
-1
) and incubated in the 
release medium (25 ml) at 37 °C in an orbital incubator (SI50, Stuart R, UK) 
operating at 100 rpm. At scheduled time intervals, 1 ml of the release medium 
was withdrawn and replaced with the same volume of fresh medium. Dox 
content in the supernatant was quantified by spectrofluorimetric assay. The 
instrument response was linear over the concentration range 0.1–2 µg ml-1 (r2 > 
0.99). The experiments were run in triplicate. The release data were fitted by the 
simple Korsmeyer–Peppas equation [56], which helps in determining whether the 
drug release deviates from Fick’s law and is described by the following equation: 
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                                                            (1) 
 
where k is a kinetic constant comprising the geometric NP features, and n is the 
release exponent characterizing the release mechanism. For a spherical geometry, 
n ≤ 0.43 corresponds to a Fickian, while 0.43 ≤ n ≤ 0.85 indicates an anomalous 
diffusion regime. 
3.3.8. Cell culture 
To test the biological effects of the NPs, human epithelial cervix carcinoma 
(HeLa) and human ovarian adenocarcinoma (IGROV-1) cell lines were used. In 
particular, the latter were chosen as a control drug-resistant system. HeLa cells 
were cultured with a complete medium, composed of DMEM with 1 g l
-1
 
glucose, containing 10% (v/v) FBS, 100 U ml
-1 
penicillin and 0.1 mg ml
-1 
streptomycin, while IGROV-1 cells were grown in RPMI 1640 with 10 % FBS 
and antibiotics. The cells were maintained in 100 mm diameter cell culture dishes 
in a humidified atmosphere at 37 °C and 5 % CO2. 
3.3.9. Nanoparticle uptake and cytotoxicity in 2D 
The cell uptake of the Dox-loaded NPs was investigated by a confocal laser 
scanning microscope (CLSM), taking advantage of the intrinsic fluorescence of 
Dox. For CLSM observations, PELGA10, PELGA20 and PELGA40 NPs were 
dispersed in cell culture medium at a final Dox concentration of 2 µg ml
-1
. A 
subconfluent layer of cells was incubated with NP suspension at 37 °C for 24 h. 
Afterwards, the cells were rinsed twice with PBS to remove non internalized NPs 
and fixed with 4 % paraformaldehyde for 20 min. The cell nuclei were stained by 
using 40, 6-diamidino-2-phenylindole (DAPI) (Sigma). The samples were 
observed at 488 nm with a water-immersion 63X objective by a CLSM 
(LSM510, Zeiss) equipped with an argon laser line. Image resolution was set to 
1024 x 1024 square pixels. The cytotoxic activity of Dox-loaded PELGA10, 
PELGA20 and PELGA40 NPs against HeLa and IGROV-1 cells was compared 
to non-treated cells, free drug and blank NPs, which were used as a control. Cell 
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survival was quantified by Alamar Blue Assay. 5 x 10
4 
cells were added to 200 µl 
of cell culture medium in each well of a 96-well plate and allowed to recover for 
24 h. After recovery, free drug, blank or drug-loaded NPs were added to the 
wells in 100 µl of medium and non-treated cells received 100 µl of medium. The 
cells were treated for 24 h, and afterwards Alamar Blue Assay was performed. 
The absorbance of Alamar Blue reagent solution was read at 570 nm and 600 nm 
by a plate reader (Wallac Victor 1420, Perkinelemer). Data were reported as 
percentage of viable cells normalized to non-treated cells. 
3.3.10. Nanoparticle uptake and cytotoxicity in 3D collagen matrices 
For the uptake and cytotoxicity of the NPs in a 3D matrix, we set up a home-
made experimental system in order to mimic a tumor ECM network in vitro. As 
shown in Fig. 2, a porous membrane was used to separate two silicon chambers, 
filled with collagen gel prepared by diluting collagen solution with 10 X 
Dulbecco’s phosphate saline buffer (D-PBS, Gibco, Life Technologies) (8:1 
volume ratio) and adjusting the pH to 7.4 by dropwise addition of NaOH and 
HCl. 1 * 10
5
 HeLa cells were suspended in 370 µl of 2.4 mg ml
-1
 collagen 
solution and poured into the larger chamber. The system was then incubated at 
37 °C for 1 h to allow collagen fibrillogenesis and, afterwards, fresh cell culture 
medium was added to the gel. After 24 h, 330 µl of 2.4 mg ml
-1
 collagen solution 
containing Dox-loaded NPs at a final Dox concentration of 2 µg ml
-1
 was poured 
into the smaller chamber at 37 °C for fibrillogenesis for about 1 h. 
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For cytotoxicity experiments, membranes with 0.05 µm or 0.65 µm pore 
diameters were used (IsoporeTM membrane filters, Millipore). In the first case, 
the pore diameter was smaller than the 
NP size, thus the devices were confined 
in the small chamber and could not 
diffuse through the collagen gel. In the 
second case, the NPs could freely 
diffuse within the collagen matrix, and 
cytotoxicity was contributed also by NP 
diffusion. Cell cytotoxicity in 3D 
matrices was evaluated by a time-lapse 
experiment by using a CellR microscope 
(Olympus) equipped with a mini-
incubator to control temperature and CO2 percentage. Images were acquired 
every 10 min for 24 h. In order to test the capability of the NPs to release Dox in 
3D matrices, the cytotoxic effect in 3D was analyzed at 1, 2 and 4 mm from the 
porous membrane. The changes in cell morphology (from stretched to round) and 
the increment of cell fluorescence, due to intracellular Dox accumulation during 
the time-lapse experiments, indicated cell death. NP cytotoxicity in 3D was 
expressed as the percentage of dead cells after 24 h as a function of the distance 
from the porous membrane. 
Prior to the cytotoxicity tests in 3D, the diffusion coefficients of the Dox and the 
NPs were determined by single-channel fluorescence correlation spectroscopy 
(FCS) in combination with CLSM. A confocal fluorescence correlation 
spectroscope, ConfoCorII (Carl Zeiss, Jena, Germany) was used. For the FCS 
studies, non-gelled collagen (200 µl) or water was poured into each chamber of 
an eight-well borosilicate coverglass (Lab-Tek, Germany) and fibrilled at 37 °C. 
The Dox or NPs were loaded into the collagen gel by overnight contacting of a 
drug solution/NP suspension in water with the fibrilled gel. The final drug and 
NP concentrations in the gel were optimized to 20 ng ml
-1
 and 0.042 mg ml
-1
, 
Figure 2. Schematic drawing of the two-
compartment experimental system used for 
experiments. Cells were embedded in 
collagen and placed in the bigger chamber, 
with free Dox or Dox-loaded NPs in 
collagen in the smaller one. The membrane 
pores were 0.05 µm or 0.65 µm for NP 
confinemen  or non-confinemen  in the 
smaller chamber. Units = mm 
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respectively. The gel or NP suspension was excited by laser light at 488 nm, and 
the laser beam was focused by a Zeiss 40 Apochromat water-immersion 
objective (Carl Zeiss, Germany). The fluorescent emission beam was mapped 
onto a pinhole in the image plane of the objective (70 µm), sent to a 530 nm LP 
filter, and then acquired on an avalanche photodiode (APD) in single-photon 
counting mode. The diffusion coefficients were derived from the normalized 
autocorrelation function [57] 
 
     
             
       
   
              
       
    ,                              (2) 
 
which describes the fluctuations of fluorescence intensity at time t,  F(t) = F(t) – 
[F(t)], and at time t +  ,  F(t +  ) = F(t +  ) – [F(t +  )], around the corresponding 
mean values [F(t)] and [F(t +  )]. The autocorrelation function gives information 
on  D, the dwell time in the confocal volume [58], which ia s prolate spheroid 
having axes ωxy and ωz. The structure parameter S = ωz/ ωxy was variable. The 
diffusion coefficients were calculated assuming that the confocal volume (which 
was estimated to be <0.04 fl) depends only on the confocal parameters (pinhole 
aperture, laser power) and the nature of the fluorescent molecule. Based on the 
previously determined diffusion coefficient of Dox in water at 37 °C (2.12 * 10
-6
 
cm2 s
-1
 [59]), the confocal volume was calculated taking into account that 
 
            ,                                             (3) 
 
where D is the diffusion coefficient of Dox and  D is the dwell time in the 
confocal volume. The confocal volume is easily derived as 
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Hence, 
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FCS experiments were run at least five times at 37 °C. 
3.3.11. Nanoparticle uptake quantification 
To evaluate the cell uptake of Rhod–PELGA10 NPs, 5 * 104 cells were seeded in 
a 24-well plate for 2D culture conditions and the same amount of cells was 
grown in 250 µl of 2.4 mg ml
-1
 collagen gel for 24 h at 37 °C for 3D culture 
conditions. Afterwards, the cells were incubated with Rhod–PELGA10 NPs 
dispersed in cell culture medium. The total amount of NPs was kept constant for 
the 2D and 3D experiments. More precisely, the Rhod–PELGA10 NP final 
concentrations were 50 µg ml
-1
 for 2D and 100 µg ml
-1
 for 3D, i.e. 500 µl and 
250 µl of NP suspension were added to the cells for the 2D and 3D experiments, 
respectively. The cells were incubated with NP suspensions for 24 h at 37 °C. 
After incubation, the cells in 2D were rinsed with PBS and lysed with 1 % Triton 
X100 in PBS. For the 3D experiments, after rinsing with PBS, the collagen gel 
was digested with 2.5 mg ml
-1
 collagenase A solution, centrifuged and the pellet 
of cells was suspended in 1 % Triton X 100 in PBS. Finally, the cell lysates were 
analyzed by a spectrofluorometer (Wallac 1420 Victor2TM, Perkin-Elmer, USA) 
by measuring the NP fluorescence intensity at λ = 543 nm. The amount of 
internalized NPs was quantified by interpolating the fluorescence intensity data  
with a calibration curve. 
3.3.12. Colocalization with LAMP2, clathrin and caveolin 1 
For indirect immunofluorescence, after NP incubation, the cells were first rinsed 
twice with PBS to remove noninternalized NPs and fixed with paraformaldehyde 
4 % for 20 min. Then, the cells were incubated with Triton X 100 0.1 % in PBS 
for 10 min and with PBS-BSA 0.5 % for 15 min at room temperature (RT). 
Caveolae were localized by first incubating samples with rabbit anti-caveolin 1 
(Abcam) primary antibodies. For lysosomes, rabbit polyclonal anti-LAMP2 
(Abcam) primary antibodies were used. Clathrin coated vesicles were localized 
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with mouse anti-clathrin monoclonal (ABR). After primary antibody incubation, 
Alexa-fluor 488 goat anti-rabbit secondary antibodies (Molecular Probes, 
Invitrogen) and Alexa-fluor 488 goat anti-mouse secondary antibodies 
(Molecular Probes, Invitrogen) were used. Afterwards, the samples were rinsed 
three times with PBS. The cell nuclei were stained with DAPI. 
Immunofluorescence analyses were performed by a confocal and multiphoton 
microscope system (Leica TCS SP5 MP). Images were acquired with a resolution 
of 1024 X 1024 pixels. Colocalization was estimated by an ImageJ software 
plugin. 
3.3.13. Statistical analysis 
In all cases, quantitative data were reported as mean value standard deviation 
(SD). The results were analyzed by one-way analysis of variance (ANOVA). A 
value of p < 0.05 was considered statistically significant. 
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3.4. RESULTS AND DISCUSSION 
3.4.1. FTIR characterization 
PLGA–PEG copolymer (namely PELGA) was synthesized and used to produce 
NPs, and the reaction scheme is reported in Fig. 1(A). FTIR spectra of PEG, 
PLGA and PELGA copolymer are presented in Fig. 1(B). The peak at 1631 cm
-1
 
of the PELGA spectrum was associated with the bending vibration of the 
absorption water in the materials. The peaks at 3423.4 and 2885.7 cm
-1
 in the 
PEG spectrum were assigned to the terminal –OH group and C–H stretching of 
CH2 groups, respectively. The peaks at 2999.0 and 2954.7 cm
-1
 in the PLGA 
spectrum are related to C–H stretching of CH3 groups, while the peaks at 2878.7 
cm
-1
 and 1754.5 cm
-1
 correlate to C–H stretching of CH2 and CDO stretching in 
PLGA, respectively. For the PELGA, the peak at 3439.2 cm
-1
 was assigned to –
OH stretching, the ones at 2961.0 and 2923.0 cm
-1
 to C–H stretch of CH3, and the 
one at 2853.4 cm
-1
 was C–H stretching of CH2. The strong peak at 1757.7 cm
-1
 
was related to CDO stretching of PELGA, indicating the formation of ester 
groups, and of the copolymer. 
3.4.2. Differential scanning calorimetry (DSC) 
The thermal properties of drug-loaded carriers are of importance in 
pharmaceutical technology since information such as melting and crystallization 
is useful to assess the physico-chemical status of the loaded drug and hence 
drug–material interactions, which are relevant for the in vitro release properties. 
DSC experiments were performed on a drug (Dox), polymers (PLGA, PEG and 
PELGA) and NPs (unloaded and Dox-loaded PELGA10 and PELGA20). Fig. 3 
depicts the corresponding DSC spectra. Native Dox exhibited a sharp 
endothermic peak at 231.5 ± 1.5 °C (Fig. 3(A)). For the polymers, PLGA showed 
a glass transition temperature (Tg) at 36.8 ± 1.2 °C, while PEG displayed a clear 
endothermic melting peak at 49.3 ± 0.3 °C. The PELGA copolymer did not 
exhibit the PEG melting temperature (Tm) and underwent a glass transition at 
24.4 ± 2.5 °C, lower compared to PLGA. This strongly suggests that short PEG 
segments plasticize the adjacent PLGA chain and the molecular weight is low, 
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thus hampering the formation of any crystalline structure. A broad and not 
relevant exothermic peak was detected around 200 °C (Fig. 3(B)–(D)). 
DSC tests were also performed on placebo and Dox loaded NPs. As shown in 
Fig. 3(E), the Tg of unloaded NPs was 23.6 ± 1.8 °C, very close to that of 
PELGA, and basically behaved as the synthesized copolymer. Likewise, the DSC 
thermogram of Dox-loaded PELGA20 NPs was basically superimposable on the 
PELGA thermogram, and no endothermic melting peak could be detected (Fig. 
3(G)), which indicates that Dox is present in the non-crystalline state in these 
NPs, and therefore that the undesired phenomenon of Ostwald ripening is 
inhibited [60].  
 
 
 
Figure 3. DSC thermograms of plain Dox (A); PLGA (B); PEG (C); PELGA (D); blank NPs 
(E); Dox-loaded PELGA10 NPs (F); Dox-loaded PELGA20 NPs (G). Heating rate was 5°C 
min
-1
. 
 
Interestingly, the thermogram of the Dox-loaded PELGA10 NPs showed the 
endothermic melting peak of Dox at 222.3 ± 7.8 °C, but strongly attenuated. This 
suggested a partial interaction between the PELGA and the Dox, which allowed 
the presence of some drug in the crystalline state. The discrepancy in the DSC 
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results relative to the PELGA20 formulation can be reasonably ascribed to the 
higher drug:polymer mass ratio in the case of PELGA10 compared to PELGA20 
NPs (1:25 versus 1:50). In the latter case, the DSC results suggest that the Dox 
could be efficiently dispersed within the PELGA and could not organize into 
crystalline structures. The amorphous drug phase results in a higher solubility, 
which in turn influences both the in vitro and in vivo dissolution features [61]. 
3.4.3. Nanoparticle characterization 
Like other amphiphilic copolymers, the PELGA emulsion formed core–shell NPs 
[62]. As shown in Fig. 4(A) and summarized in table 1, the PELGA10 and 
PELGA20 NPs were spherical and possessed <100 nm diameters and 
polydispersity indices ranging from 0.13 to 0.16, indicating a narrow overall size 
distribution. The NP size increased with PELGA concentration in the organic 
phase of the emulsion due to a poorer dispersibility of the organic phase, while 
the ζ -potentials were mildly negative and decreased slightly with increasing 
polymer concentration, which suggests that the hydrophilic PEG segments and 
non-ionic Pluronic partially mask the carboxylic groups of the PLGA chains. The 
Dox entrapment efficiency increased with increasing PELGA concentration due 
to the increasing viscosity of the organic phase which hampered drug leakage 
towards the external aqueous phase (Table 1). 
 
 
Table 1. Size, polydispersity index (PDI), zeta potential and entrapment efficiency of Dox-
loaded NPs. 
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NP stability is important in view of NP use for cell experiments and 
pharmaceutical applications. The stability of the devices was assessed by 
incubation for 24 h in cell culture medium and size measurements of the NPs 
after incubation in PBS. The NP diameters were basically constant in all cases 
(the mean diameters after incubation were 79.2 ± 5.7, 90.5 ± 5.0 and 175.8 ± 4.3 
nm for PELGA10, PELGA20 and PELGA40 NPs, respectively), and no self-
aggregation of the medium could be detected. Actually, due to the double 
emulsion preparation technique, PEG segments are exposed on the NP surface, 
thus contributing to reduction of the interfacial tension between the devices and 
the suspending adsorption and self-aggregation. These findings confirmed 
literature results on PEG-conjugated NPs, which were demonstrated to be stable 
in water at 4 °C for periods ranging from weeks to months [15, 63, 64]. Prior to 
the cell experiments, rhodamine release from the Rhod–PELGA10 NPs was 
assessed in the same conditions as the PELGA NPs. 
As expected, due to the very stable amine bond between PLGA and the dye, no 
Rhod release was evidenced in the time frames of either the cellular experiments 
(24 h) or the drug release kinetics. 
3.4.4. In vitro Dox release kinetics 
In vitro Dox release profiles from the PELGA10 and PELGA20 NPs are shown 
in Fig. 4(B) and (C). It was necessary to study the Dox release profiles at 
different pH values (7.4, 6.8 and 5.0) to simulate the conditions of normal ECM, 
tumor ECM and lysosomes. In all cases, a 24 h burst followed by a slower 
release phase was found. The PELGA20 NPs gave a one day burst fraction 
strongly dependent on the pH (18.1 % at pH 7.4 and 60.7 % at pH 5.0). In the 
case of the PELGA10 NPs the burst was less variable with the pH (30.2 % at pH 
7.4 and 45.4 % at pH 5.0). In particular, the Dox release rate from the PELGA 
NPs decreased with increasing PELGA concentration in the organic phase of the 
emulsion and with increasing pH. To investigate the mechanisms of NP 
unloading, Dox release profiles were plotted as a function of t
1/2 
(Fig. 4(B)).  
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In all cases, after a one day burst a second linear region followed, with a slope 
relatively constant with the pH and basically independent of the formulation, 
while the one day burst strongly depended on both the formulation and the pH. 
To envisage whether the Dox discharging from the PELGA NPs was driven by 
diffusion, the release data were fitted to equation (1). The estimated parameter 
values are listed in Table 2. The fitting results showed that k decreased slightly 
with the pH, with a strong dependence for the PELGA20 NPs, while n increased 
slightly/strongly with the pH for the PELGA10/PELGA20 NPs, respectively.  
 
Figure 4. Morphology and release features of PELGA nanoparticles. A: TEM micrographs of 
Dox loaded NPs. The bar: is 100 nm for PELGA10 and PELGA20 nanoparticles and 200 nm 
for PELGA40 nanoparticles. B: In vitro release profiles of Dox from PELGA10 and PELGA20 
NPs as a function of square root of time. C: release data as a function of time. Solid lines 
represent curve fitting. Symbols: (▲) pH = 5.0; () pH = 6.8; () pH = 7.4.  
 
In particular, the n values showed that the release was driven by diffusion in all 
cases, and the corresponding increase of the release rate in acidic conditions was 
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ascribed to an enhanced NP porosity during PELGA degradation, which further 
promoted a diffusion controlled release regime. 
Indeed, drug desorption/diffusion and PELGA degradation occurred 
simultaneously and, in all cases, n ranged from 0.223 to 0.404 (n < 0:43), 
indicating that drug desorption/diffusion is faster than polymer 
degradation/erosion. In the case of the PELGA20 NPs (at pH 7.4), a threshold 
value of n is approached, suggesting that the PELGA degradation rate is less 
negligible compared to Dox transport at physiological pH and at a higher 
polymer concentration. 
 
 
Table 2 – Peppas-Korsmeyer parameter estimates for Dox release from PELGA NPs. 
Thus, Dox release from PELGA NPs primarily depends on drug diffusion and is 
secondarily affected by PELGA degradation. Indeed, in a previous work [65], we 
demonstrated that the autocatalytic degradation of PLGA microspheres produced 
by double emulsion was not affected by the polymer concentration in the organic 
phase of the emulsion, even at much higher polymer concentrations in the 
organic phase of the emulsion (10 %–20 % w/v versus 1 %–2 %–4 % w/v in this 
work). Thus, at the nanoscale level and with lower PLGA concentration in the 
organic phase of the emulsion, the formulation is not expected to affect the 
degradation pattern, and the weak dependence on pH of the Dox release rate 
from the PELGA10 NPs could be ascribed to their higher nanoporosity. In 
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contrast, the strong dependence of the Dox release kinetics from the PELGA20 
NPs on the pH of the release medium strongly suggests a nonnegligible role of 
PELGA degradation, ascribed to a more efficacious Dox entrapment within the 
NP matrix. The PELGA20 NPs showed a more desirable release behavior as it 
was more sensitive to pH and more sustained at physiological pH. 
3.4.5. Nanoparticle uptake 
The uptake of the Dox-loaded PELGA10, PELGA20 and PELGA40 NPs in 
HeLa and IGROV-1 cell lines was systematically studied and compared to the 
internalization of free, non-encapsulated Dox. After 24 h incubation with a Dox-
loaded NP suspension, a cytoplasmic distribution of fluorescence due to Dox was 
observed in HeLa cells. In particular, CLSM images showed that the NP uptake 
by HeLa cells was slightly more extensive in the case of the smaller, Dox-loaded 
PELGA10 NPs (Figs. 5(D)–(F)) compared to the PELGA20 NPs (Figs. 5(G)–
(I)), which had a higher mean diameter (88.5 versus 77.2 nm). Moreover, the 
fluorescence appeared to be non-homogeneously diffused within the cells, but 
rather organized in discrete spots, mainly located in a perinuclear region, which 
strongly suggests Dox confinement within the NPs. Conversely, free Dox was 
preferentially localized within the cell nuclei, as evidenced by colocalization with 
DAPI staining (Figs. 5(A)–(C)). Upon Dox release in the endosomal or 
lysosomal lumen, the cell nuclei were expected to turn green. In our case, 
however, the PELGA NPs displayed prolonged release features and, therefore, in 
the first 24 h of delivery, only the burst fraction could be released and reach the 
intracellular space. These findings are consistent with previous results, which 
showed that nuclear penetration may take place in the case of free drug or of NPs 
with a diameter of around 4 nm [66], much smaller than the NPs prepared in this 
work. It must also be underlined that an increase in NP size leads to a drastic 
decrease of the cellular uptake amount. Indeed, after 24 h incubation with 
PELGA40 NPs (mean diameter: 174.9 nm), very few or no NP aggregates could 
be detected within the cytoplasm of the HeLa cells, while a weak cell nucleus 
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green staining was observed (Figs. 5(J)–(L)), probably due to the released Dox 
in the time frame of the cell experiments. 
 
Figure 5. Confocal laser scanning microscope images of HeLa cells incubated for 24 hours 
with 2 µg mL
-1
 free Dox (A-C); Dox-loaded PELGA10 NPs (D-F); Dox-loaded PELGA20 NPs 
(G-I); Dox-loaded PELGA40 NPs (J-L).  A, D, G, J: DAPI staining of cell nuclei. B, E, H, K: 
intracellular localization of Dox; C, F, I, L: merge. Magnification bar: 50 µm. 
In the case of the IGROV1 cells, a negligible NP internalization was observed for 
the PELGA10 and PELGA20 formulations (Figs. 6(D)–(L)), and also the free 
Dox uptake was lower than for the HeLa cells, as shown in Figs. 5(A)–(C) and 
6(A)–(C). Actually, it has been reported that IGROV1 cells show a very low 
doubling time and are more resistant to drug treatments [67]. Thus, our results 
confirm the resistance to treatment of IGROV1 cells and, more importantly, a 
specific localization of NPs within HeLa cells, which was mainly attributed to 
the size of the devices.  
Free Dox
PELGA10 NPs
PELGA20 NPs
PELGA40 NPs
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Figure 6. Confocal laser scanning microscope images of IGROV1 cells incubated for 24 hours 
with 2 µg mL
-1
 free Dox (A-C); Dox-loaded PELGA10 NPs (D-F); Dox-loaded PELGA20 NPs 
(G-I); Dox-loaded PELGA40 NPs (J-L).  A, D, G, J: DAPI staining of cell nuclei. B, E, H, K: 
intracellular localization of Dox; C, F, I, L: merge. Magnification bar: 50 µm. 
 
To the best of our knowledge, NP uptake mostly occurs by endocytosis or 
potentially pinocytosis. In this latter case, the NPs experience lysosomal pH 
(around 5), which strongly accelerates the Dox release from the PELGA20 NPs 
(Fig. 4(B)), while having a weaker influence on the release kinetics from the 
PELGA10 NPs. Taken all together, these results suggest that the PELGA20 
formulation is more promising in the perspective of intracellular drug delivery 
due to the drug delivery being more strongly dependent on the pH.  
Many works report on mechanisms underlying PLGA NP internalization. 
Depending on the cell type and the NPs’ technological and physico-chemical 
features (such as NP size, surface charge, etc), several authors have demonstrated 
Free Dox
PELGA10 NPs
PELGA20 NPs
PELGA40 NPs
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that PLGA NPs can follow different uptake pathways [68-71]. Thus, to elucidate 
PELGA NP uptake by cells, we performed indirect immunofluorescence analyses 
of specific endocytic markers. As shown in Fig. 7, Rhod–PELGA10 NPs do not 
use caveolae-mediated endocytosis (Fig. 7(A)), though they partially colocalize 
with clathrin (Fig. 7(B)) and LAMP2 (Fig. 7(C)), thus indicating that Rhod–
PELGA10 NPs enter by clathrin coated pits and reach lysosomes. In particular, 
by using ImageJ analysis software, we found 0.51 % colocalization between 
clathrin 1 and NPs and 1.72 % colocalization between LAMP2 and NPs. 
 
 
Figure 7. Colocalization between Rhod PELGA 10 NPs and endocytic markers. A. Caveolin 1 
(green), NPs (red) and DAPI (blue); B. Clathrin (green), NPs (red) and DAPI (blue); C. 
LAMP2 (green), NPs (red) and DAPI (blue). Magnification bar: 20 µm. 
 
3.4.6. Nanoparticle cytotoxicity 
To demonstrate how the formulation and sub-100 nm size affect NP uptake, we 
tested the in vitro cytotoxic response of HeLa and IGROV1 cell lines elicited by 
Dox-loaded PELGA NPs. The biological activity was quantified using the 
Alamar Blue cytotoxicity assay. Fig. 8 shows the cell viability percentage of 
treated cells normalized to non-treated cells. The results indicate a significant 
cytotoxic effect after 24 h of incubation when free Dox at 2 µg ml
-1
 is used. In 
particular, after 24 h of incubation with free drug, HeLa and IGROV1 cells were 
50 % and 90 % viable, respectively, in agreement with previous literature results 
[67]. In the case of incubation with drug-loaded PELGA10 and PELGA20 NPs, 
the cytotoxic response was less significant and basically the same for both NP 
CBA
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formulations. In particular, a slight reduction (around 20 %) of HeLa cell 
viability was observed after exposure to Dox-loaded NPs, thus demonstrating 
that NPs able to sustain Dox release induce a lower cytotoxicity compared to the 
free drug at the same concentration. In the case of IGROV1 cells, no cytotoxic 
effects were observed. 
 
 
Figure 8. Cytotoxicity assay in 2D cell culture conditions. Percentage of viable HeLa and 
IGROV1 cells treated with 2 µg mL-
1
 free Dox and with Dox-loaded PELGA10, PELGA20 and 
PELGA40 NPs for 24 hours. p < 0.05. 
 
Dox-loaded PELGA40 NPs elicited a weaker cytotoxic response compared to the 
smaller PELGA10 and PELGA20 NPs. This effect was immediately related to a 
higher diameter and subsequent inability to enter cells. Control experiments were 
carried out using placebo NPs, which were non-cytotoxic in all formulations 
(data not shown), suggesting that the low cytotoxicity could be ascribed to the 
low percentage of Dox released. The results of the 2D cytotoxicity assays were 
consistent with the drug release kinetics and NP uptake observations. Indeed, 
after 24 h in buffer medium at pH 7.4, the percentage of released Dox was 30.3 ± 
4.0 %, 18.8 ± 1.8 % and 0.55 ± 0.3 % for the PELGA10, PELGA20 and 
PELGA40 NPs, respectively. These values approximately correspond to Dox 
concentrations of 0.60, 0.35 and 0.01 µg ml
-1
 in the cell culture medium, much 
lower than the concentration of free Dox (2 µg ml
-1
) used to incubate the cells. 
Moreover, CLSM observations revealed that the NPs tend to localize within the 
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cell cytoplasm, and this contributes to make them less cytotoxic than free Dox, 
which tends to accumulate into the nucleus. Actually, the intracellular location is 
expected to play an important role, as it directly correlates with the cytotoxicity 
response and pharmacological effect of internalized NPs. In fact, it has recently 
been suggested that PLGA–PEG NPs are translocated via a lysosomal pathway 
after uptake [72]. Lysosomes contain varying concentrations of hydrolases, 
which promote NP degradation and therefore Dox release and transport towards 
the cell nucleus and, ultimately, the cytotoxic effect. The latter is more 
significant in the case of PELGA10 and PELGA20 NPs compared to PELGA40 
NPs, and this can be reasonably ascribed to the decrease of device nanoporosity 
with increasing PELGA concentration in the organic phase of the emulsion. All 
considered, the results of the cytotoxicity assays confirmed that HeLa cells are 
much more vulnerable than IGROV1 to both non-encapsulated and encapsulated 
Dox. Furthermore, the data clearly show that the cytotoxic response is promoted 
by the size-dependent possibility of NP internalization, and is more significant in 
the case of the PELGA20 devices, which showed a 24 h burst release that 
strongly increased when the NPs experienced low lysosomal pH, which is related 
to a higher concentration of intracellular free Dox diffusing to the nucleus. 
To study the effect of NP size on cell toxicity in 3D, we incubated cells with 
PELGA NPs in matrices made up of collagen, which is the major constituent of 
the ECM in malignant tumors [73]. Experiments were performed on HeLa cells, 
which were more susceptible to Dox compared to the IGROV1 cell line. In 
particular, the internalization and cytotoxicity of PELGA10 and PELGA20 NPs 
in 2D were not significantly different and, for this reason, the cytotoxic effect of 
only PELGA10 and PELGA40 NPs was assessed, to highlight the importance of 
NP size in cell viability. The cytotoxic response was quantified after 24 h of 
culture and expressed in terms of percentage of dead cells in 3D collagen 
matrices upon contact with free Dox or Dox-loaded NPs. HeLa cells were grown 
in 2.4 mg ml
-1
 collagen in the presence of free Dox and Dox-loaded PELGA10 or 
PELGA40 NPs, confined in the smaller chamber of the experimental system 
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(schematically drawn in Fig. 2), separated from the cell containing chamber by a 
porous membrane whose pore diameter (0.65 µm) was higher than the mean size 
of the NPs, thus allowing particle diffusion through the collagen. After 24 h of 
culture in the presence of free Dox or Dox-loaded particles, the cell morphology 
changed from stretched to round and an increment in cell fluorescence, indicating 
an intracellular accumulation of Dox, was observed (Fig. 9(A2)). In particular, 
the cytotoxic response was lower with PELGA40 compared to PELGA10 NPs, 
and this can be immediately correlated with the lower 24 h burst release observed 
with the PELGA40 formulation, as shown in Fig. 4(B) and discussed in this 
section. 
The percentage of dead cells after 24 h of culture in collagen matrices indicated a 
cytotoxic effect of both free Dox and Dox-loaded PELGA NPs. As expected, the 
cytotoxicity decreased with increasing distance from the porous membrane (Fig. 
9(B)). However, a contribution of particle transport in the collagen to the 
cytotoxic response cannot be excluded. Indeed, we observed the uptake of 
placebo fluorescent rhodamine-conjugated PELGA10 NPs in HT1080 cells 
seeded for 24 h within 2.4 mg ml
-1
 collagen gel (data not shown), indicating NP 
diffusion through the 3D matrix. Likewise, the transport of smaller PELGA10 
NPs within the collagen gel is obviously enhanced compared to larger PELGA40 
NPs, and therefore the cytotoxic effect in 3D is dependent on both particle 
diffusion within the matrix and Dox release. Furthermore, the amount of Dox 
released at neutral pH after 24 h must be considered; this is higher from 
PELGA10 than from PELGA40 NPs. Thus, to discriminate the contributions of 
particle diffusion and drug release to toxicity, the same experiments were carried 
out under NP confinement, using a membrane pore size of 0.05 µm, smaller than 
the particle size. Compared to standard 2D cell cultures, these conditions better 
resemble the in vivo tumor environment since, in most cases, device penetration 
through tumor interstitium is hampered after extravasation [74]. 
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Figure 9. Cytotoxicity against HeLa cells in 3D collagen gel. A. Results of cytotoxicity assay in 
3D collagen matrices in presence of free Dox and Dox-loaded NPs. A1: Microscope images of 
HeLa cells in 3D culture conditions obtained by CellR after 24h of incubation with Dox-loaded 
PELGA10 NPs. DAPI staining of cell nuclei. A2: brightfield and fluorescence image 
overlapping. Green fluorescence indicates Dox intracellular accumulation. Magnification bar: 
200 µm. B: Percentage of dead cells in presence of free Dox, PELGA10 and PELGA40 NPs 
with membranes having 0.05 µm (Confined) and 0.65 µm (Non confined) pore diameters, 
calculated at 1, 2 and 4 mm from the porous membranes. p < 0.05. 
In our experiments, the PELGA10 NPs elicited a cytotoxic effect which was 
lower and decreased with increasing distance from the porous membrane, while 
the PELGA40 particles did not induce any cytotoxicity (Fig. 9(B)). These results 
can be related to hampered transport of the devices through the gel matrix. 
Actually, a fraction of the PELGA10 NPs can cross the membrane pores, thus 
contributing to the cytotoxicity with their cargo features and burst release. In 
contrast, the larger PELGA40 NPs are expected to be mostly confined in the 
small chamber. Therefore, the lack of cytotoxicity of the PELGA40 NPs can be 
mainly attributed to a sublethal released amount of Dox at any distance from the 
porous membrane. These data show that, also in 3D matrices, Dox delivery from 
NPs is effective and, in particular, the cytotoxicity strongly depends upon the 
distance from the deposition site of the NPs (i.e., the porous membrane). On the 
other hand, with both 0.05 and 0.65 µm pore sizes, and at any distance from the 
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membrane, the cytotoxicity due to the free Dox was higher compared to the NPs, 
and basically independent of the size of the membrane pores. This is consistent 
with the FCS results, which showed that the diffusion coefficients (D) of Dox at 
37 °C in water and collagen are quite similar, i.e. 2.12 ± 0.37 [59] and 1.80 ± 
0.09 10
-6
 cm
2
 s
-1
, respectively. On the other hand, the diffusion coefficient of 
Rhod–PELGA10 NPs decreases drastically in collagen gel. In particular, the D 
values are 4.58 ± 0.41 10
-8
 cm
2
 s
-1 
in water and 8.50 ± 5.44 10
-9
 cm
2
 s
-1
 in 
collagen. To further demonstrate the effect of the 3D collagen matrix on NP 
diffusion and cellular internalization, we quantified the Dox-free Rhod–
PELGA10 NP uptake in HeLa cells cultured in 2D and 3D conditions. As shown 
in Fig. 10, the results demonstrate a higher nanoparticle uptake in 2D than in 3D 
after 24 h of incubation, in agreement with FCS measurements, indicating that 
collagen gel strongly hampers NP transport compared to water, thus limiting NP 
uptake in 3D. 
 
Figure 10. Rhod-PELGA10 NP uptake by HeLa cells in 2D versus 3D culture conditions.  
p < 0.05. 
 
To summarize, our findings clearly demonstrate that the cytotoxic effect of NPs 
decreases with increasing device size, drug release kinetics and distance from the 
porous membrane. Indeed, 3D in vitro tumor models have been previously 
developed with the aim of studying the effect of anticancer drugs in tissue 
analogs, demonstrating that cell responses in 2D and 3D matrices are drastically 
different [31, 73, 75]. In this study, the cytotoxicity was much lower when the 
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NPs were confined in a compartment separated from the cells while, when the 
NPs were not confined, the cell cytotoxicity in 3D was promoted also in the case 
of the PELGA40 NPs, which released a much smaller amount of Dox in 24 h. 
This indicates that larger devices can also diffuse within the collagen matrix. 
Taken all together, the results show that, assuming the EPR effect and 
subsequent NP accumulation in the interstitial area, Dox is less cytotoxic when 
encapsulated in NPs also in 3D matrices. In particular, when 0.05 µm pore size is 
used, only small NPs are cytotoxic, due to the fraction travelling across the 
collagen gel, therefore highlighting the importance of NP transport through the 
matrix. This clearly demonstrates the importance of the combination of sub-100 
nm NP size and controlled release features as key parameters governing NP 
diffusion and Dox release within 3D matrices. Interestingly, the produced NPs 
could elicit, in the 3D culture conditions employed in this work, a cytotoxic 
response at distances of the order of some mm from the deposition site, due to 
both drug release and device transport through the collagen matrix. It must be 
underlined that the collagen concentrations used in this work do not resemble the 
actual in vivo conditions of a tumor matrix, which is intrinsically unsteady and 
fibrotic, and contains many dead end capillaries. However, <100 nm devices with 
controlled release features are potentially promising as they may travel through 
tumor interstitium and exert their cytotoxic effect. In particular, Fig. 9(B) 
indicates that by matching proper NP size and controlled release features (i.e. 
optimizing the polymer concentration in the organic phase of the emulsion), a 
cytotoxic response can be elicited by a device traveling through collagen, which 
is strongly favored by size reduction. In addition, we showed that PELGA40 
NPs, even if they possess a diameter suitable for EPR, are basically unable to 
induce cell death when in confinement conditions, which further underlines the 
importance of NP diffusion to carry the drug in the proximity of target cells.  
 
 
 
90 
 
3.5. CONCLUSIONS 
In this work, PEG was covalently bound to PLGA and the resulting PELGA 
copolymer was used to fabricate biodegradable NPs by a modified double 
emulsion technique to obtain sub-100 nm cargos for pH-dependent drug delivery 
to tumors. PELGA10 NPs could not provide a relevant response to pH, but Dox 
release was sustained at neutral pH and with high PELGA concentration in the 
organic phase of the emulsion; at acidic pH, drug release was much faster 
(around 75 % in 5 days for PELGA20 NPs). Cellular studies showed that, 
depending on the NP formulation and size, smaller PELGA NPs were effectively 
internalized by HeLa cells, while only a small amount of NPs could enter 
IGROV1 cells. In contrast, NPs with larger diameters (around 175 nm) could not 
be internalized by either cell population. In all cases, the NPs were less cytotoxic 
compared to free Dox, depending upon NP size and formulation and drug release 
kinetics. 3D experiments on HeLa cells showed a fundamental contribution of 
the NP size to the cell death rate, in that an increase in cytotoxicity at any 
distance was related to the diffusion of NPs within 3D constructs. More 
importantly, the smaller NPs could diffuse in collagen matrices for some mm, 
which is a relatively long diffusion path. 
Overall, these findings underline that, even if NP uptake can promote 
cytotoxicity, the results obtained in 3D with PELGA40 NPs (which cannot enter 
cells) show that some cell death can be elicited even in the absence of NP 
internalization. 
This suggests a new possible paradigm for controlled drug delivery in tumors, 
which is generally considered to be triggered by NP uptake by target cells. 
Particle size is a major feature from both a technological and a biological 
standpoint and must be properly taken into account to engineer the NP 
formulation and fabricate safe devices for the prolonged delivery of 
chemotherapeutic drugs and for reliable cell uptake/cytotoxicity studies. The 
results can be used as a basis to study NP applications for safe delivery of 
antitumor drugs.  
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CHAPTER 4 
 
Engineered nanoparticles with cleavable domains for safe 
delivery of doxorubicin 
 
4.1. ABSTRACT 
The incorporation of stimuli-responsive cassettes in engineered NPs is promising 
in achieving controlled and localized release of drugs, offering the chance to 
improve their therapeutic effects. Indeed, the localized delivery of anticancer 
drugs is mandatory to avoid or reduce the unwanted side effects to healthy cells, 
organs and tissue elicited by the cytotoxic drugs, and to increase the drug 
bioavailability and fraction accumulated in tumor. Although, a number of 
strategies to deliver drugs to target sites have been developed, physical obstacles 
to NP penetration within tumors due to aberrant vasculature and extracellular 
matrix (ECM) still remain to overcome. In the light of these considerations, the 
preparation of NPs able to safely carry a chemotherapic drug and release it 
specifically within tumor sites, possibly at extracellular level, is particularly 
attractive in the field of controlled drug delivery.       
In this view, we report on the design of a novel nanocarrier, able to safely carry 
doxorubicin (Dox) in tumor tissues, and to respond to matrix metalloprotease-2 
(MMP2) enzyme, which is over-expressed in ECM of tumors. Specifically, two 
MMP2 sensitive peptides were used as cleavable linkers between Dox and 
polyethylene glycol (PEG) to form a polymer-peptide-drug conjugate, working 
as a tumor-activated prodrug (TAP). The obtained TAP was then attached to the 
surface of 200 nm carboxyl-modified polystyrene model nanoparticles (NPs). 
The resulting TAP conjugated NPs were characterized in vitro for their release 
features at different MMP2 concentrations, in order to identify the minimum 
bioactive enzyme dose-response, and for their cytotoxic effect on three different 
human cell types, namely fibrosarcoma cell line (HT1080), primary dermal 
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fibroblasts (HDF) and umbilical vein endothelial cells (HUVECs), as models of 
tumor and healthy tissues. Results showed that Dox release from TAP NPs was 
specifically triggered by MMP2 cleavage and it was also dependent on MMP2 
enzyme concentration. Furthermore, the produced NPs were cytotoxic against all 
cell lines in presence of MMP2 enzyme. On the contrary, no cytotoxic effect was 
observed for TAP NPs in absence of MMP2 pre-treatment, even if these systems 
could be internalized by cells. Taken all together, these data demonstrated the 
potentiality of TAP NP systems in the light of translating the same TAP 
production technology to biodegradable systems intended for the “on-demand” 
delivery of cytotoxic anticancer drugs. 
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4.2. INTRODUCTION 
The use of nanoparticles (NPs) for the controlled release of anticancer drugs has 
been well studied in recent years [1-3]
 
and is considered promising to increase 
the in vivo efficacy of the delivered drugs. The localized delivery of anticancer 
drugs is mandatory to avoid or reduce the unwanted side effects to healthy cells, 
organs and tissues elicited by the cytotoxic drugs, and to increase the drug 
bioavailability and fraction accumulated in tumor [4]. Actually, passive targeting 
obtained by the enhanced permeability and retention (EPR) effect is often 
insufficient to ensure an effective drug dose to the tumor site [5]. On the 
contrary, active targeting can allow a higher drug selectivity towards tumors by 
using suitable moieties so as to target the receptors overexpressed at the tumor 
site [6, 7] and enhance specific cellular uptake/internalization through receptor-
mediated endocytosis [8-10]. For example, monoclonal antibodies (mAbs) [11-
14] and small molecules such as folate [15] and galactose [16, 17], are commonly 
used as targeting ligands for NP formulations. Besides that, it must also be 
considered that in vivo, a number of biochemical and physical obstacles hamper 
NP and/or drug cellular internalization, and this generally results into a 
drastically lowered efficacy of the treatment. Indeed, even if a number of 
strategies to deliver drugs to tumor sites have been developed, physical obstacles 
to NP penetration within tumors due to aberrant vasculature and extracellular 
matrix (ECM) still remain to overcome [18]. In the light of this consideration, the 
preparation of NPs able to safely carry a chemotherapic drug and release it 
specifically within tumor sites, possibly at the extracellular level, is particularly 
attractive in the field of controlled drug delivery. In this context, physiological 
variations naturally occurring within tumors are interesting for the preparation of 
stimuli-responsive prodrugs or nanocarriers reacting to specific endogenous 
stimuli, such as pH and enzymes [19, 20]. This challenging goal can be attained 
by conjugating the drug(s) to specific bioactive molecules cleavable by the 
physiological stimulus. Actually, many anticancer drugs, such as methotrexate, 
paclitaxel, cisplatin and doxorubicin (Dox), have been specifically delivered to 
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tumor tissues after conjugation to polymers through bioactive molecules [21-24]. 
In tumors, many proteolytic enzymes, involved in a number of biological 
mechanisms and catalytic activities related with tumor progression, are 
overexpressed [25, 26]. In particular, matrix metalloproteinase-2 (MMP2, also 
known as gelatinase A) is a 72 kDa enzyme belonging to the matrix 
metalloproteinase family, [27] present in high concentrations at active tumor sites 
[28]. MMP2 hydrolyzes type IV collagen, which is a major constituent of tumor 
extracellular matrix (ECM), thus resulting in enhanced tumor progression [29], 
invasion and angiogenesis [30]. Thus, in this work MMP2 was chosen as the 
biological signal to be exploited to induce the release of drugs in those tissues in 
which the enzyme is overexpressed.  
In literature, previous studies were mainly centered on the development of 
nanoparticles (NPs) inhibiting MMP2 action and therefore tumor progression. 
For example, iron-oxide NPs conjugated to chlorotoxin via poly(ethylene glycol) 
(PEG) silane functionalized with amine, were able to deactivate MMP2 on tumor 
surface, thus inhibiting cell invasion more efficiently compared to the peptide 
alone [31]. In another study, 50 nm magnetite NPs, functionalized with a specific 
protein (biotin or neutravidin) and conjugated to polyethylene glycol (PEG) by 
means of an MMP-sensitive substrate, were produced. The presence of high 
MMP concentrations caused the loss of PEG and therefore the self-assembly of 
NPs, which remained as aggregates in tumor sites [32]. 
Here we report on the design of a model NP, responding to MMP2 and releasing 
Dox only after enzyme exposure [33]. Two MMP2 cleavable peptides NH2-Pro-
Leu-Gly-Ser-Tyr-Leu-COOH (Mw = 648.76 Da; namely: pep A) and NH2-Gly-
Pro-Leu-Gly-Ile-Ala-Gly-Gln-COOH (Mw = 711.82 Da; namely: pep B) were 
used as sensitive linkers between Dox and PEG linker (Mw = 3500 Da), to form 
a polymer-peptide-drug conjugate, working as a tumor-activated prodrug (TAP). 
In both peptides the MMP-driven cleavage occurs near Gly unit. The obtained 
TAP was then attached to the surface of 200 nm carboxyl-modified polystyrene 
(PS) model NPs. PEG is a steric shield for NPs, and, when in tumor 
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microenvironment, the peptide is expected to be cleaved by the overexpressed 
extracellular MMP2, thus triggering Dox release. The resulting TAP-conjugated 
PS NPs were characterized for their in vitro release features at different MMP2 
concentrations in order to identify the minimum bioactive enzyme dose-response. 
NP cytotoxicity was tested in vitro against three different human cell types, 
namely fibrosarcoma HT1080 cell line, primary dermal fibroblasts HDF and 
umbilical vein endothelial cells HUVECs, as models of tumor and healthy 
tissues. 
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4.3. MATERIALS AND METHODS 
4.3.1. Chemicals  
Doxorubicin Hydrochloride (purity > 99%) was purchased from Discovery Fine 
Chemicals (UK). N,N-diisopropylethylamine (DIEA, or Hünig's base), O-
benzotriazole-N,N,N’,N’-tetramethyluronium–hexafluoro-phosphate (HBTU), 
anhydrous N,N-dimethylformamide (DMF), piperidine, 1,1′-
Carbonyldiimidazole (CDI), Trifluoroacetic acid (TFA), 2-(N-Morpholino) 
ethanesulfonic acid (MES) sodium salt, p-aminophenylmercuric acetate 
(APMA), acetonitrile (ACN) and water (HPLC grade) and buffer solutions were 
obtained from Sigma-Aldrich (USA). Fmoc-NH-PEG-COOH (Mw = 3500 Da) 
was obtained from JenKem Technology Inc. (USA). 200 nm polystyrene (PS) 
nanoparticles (NPs) modified on the surface with carboxyl groups (1% solid 
content), were obtained from Phosphorex (PolyspherexTM PS-COOH, 
Phosphorex Inc., USA). Recombinant Human Matrix metalloproteinase-2 
(MMP2) from Peprotech Inc. (Peprotech, USA) was used. Milli-RO 10 Plus 
distilled and deionized water (Millipore, USA; 18MΩ resistance) was used. 
4.3.2. Synthesis of MMP2-sensitive peptides 
MMP2 sensitive peptides (NH2-Pro-Leu-Gly-Ser-Tyr-Leu-COOH, namely 
peptide A; NH2-Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln-COOH, namely peptide B) 
were synthesized manually using the standard solid-phase 9-
fluorenylmethoxycarbonyl (Fmoc) method [34]. A Wang resin carrying a free C-
terminus for the selective binding of Dox in solution was used. The identity of 
the purified peptides was confirmed by electron spray ionization liquid 
chromatography-mass spectrometry (ESI LC-MS) using a Phenomenex 
(Torrance, CA) C18 column (4.6x250 mm size, 5 µm particle size) eluted with a 
0.1 % v/v TFA solution in water (solvent A) and acetonitrile (solvent B) solvent 
mixture. A linear gradient from 15 to 95 % solvent B over 20 min at a flow rate 
of 1 ml/min was used on a Thermo electron MSQ surveyor ESI-LC MS 
spectrometer. 
102 
 
4.3.3. Synthesis of Fmoc-Peg 3500-MMP2 peptide conjugates 
The coupling reaction of Fmoc-PEG-COOH with MMP2 sensitive peptides 
linked on resin was performed manually using Fmoc-PEG-COOH/HBTU/DIPEA 
(1.2 eq). To verify the reaction progress, the presence of the Fmoc group on the 
peptides was followed spectrophotometrically by analytic RP-HPLC on a 1220 
Infinity LC System (Agilent Technologies Inc. US), analyzing crude conjugates 
from test cleavage. The peptides were then purified to homogeneity by 
preparative reverse-phase high-pressure liquid chromatography (RP-HPLC) 
using a Shimadzu class LC10 equipped with a diode array detector (SPD-
M10AV). The samples were injected in a Phenomenex (Torrance, CA) C18 
column (22x250 mm size, 5 µm particle size) eluted with a 0.1 % v/v TFA 
solution in water (solvent A) and acetonitrile (solvent B) solvent mixture. A 
linear gradient from 15 to 95% solvent B over 20 min at a flow rate of 20 
mL/min was used. The collected fractions were lyophilized for 48 h at -54.6°C 
(Heto powerDry PL6000, Thermo electron Corp., USA) and analyzed by 
analytical RP-HPLC as perviously resported.  
4.3.4. Synthesis of the MMP2 sensitive tumor activated prodrug (TAP) 
Fmoc-PEG-peptide-Dox conjugates were synthesized using HATU as a coupling 
reagent. One equivalent of PEG-peptides sequences and doxorubicin 
hydrochloride (1.5 Eq) were dissolved in anhydrous DMF, and DIEA (2 Eq) was 
added. The resulting solution was stirred 15 min at 4°C in dark. Afterwards, 
HATU (1.5 Eq) solution in DMF was added and the reacting mixture was stirred 
overnight at room temperature. Reaction was monitored by analytical RP-HPLC 
as reported previously. The synthesis of the conjugate was verified by assessing 
of the absorption spectra of Fmoc and Dox on the peptide. Afterwards, to remove 
the protective Fmoc group from the conjugate, piperidine was added into the 
reactor to a final 40 % v/v solution in DMF. The reaction mixture was then 
precipitated from DMF solution with cold ethyl ether. The crude mixture was 
dissolved in ACN/water containing 0.1 % v/v TFA, purified by preparative RP-
HPLC and lyophilized as described in the previous section.  
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 4.3.5. Preparation and characterization of TAP- conjugated nanoparticles 
TAP-conjugated NPs were prepared by superficially binding the obtained TAPs 
on PS-COOH NPs, which were washed three times with 50mM MES buffer (pH 
= 6.0) solution prior to use. Then, 10 mg of TAP were added to 1 mL NP 
suspension (1 % w/v) in MES buffer solution; the resulting suspension was 
stirred 15 minutes at room temperature and 2 mg CDI were added. The pH of the 
suspension was adjusted to 6.5 by dropwise addition of 0.05 M HCl, and 
continuously stirred for further 2 h to allow reaction completion. Afterwards, the 
suspension was washed three times with distilled water using a concentrator 
membrane (Spin-X UF 500, Corning Corp., UK, 100 kDa molecular weight 
cutoff). The washing solutions were collected to measure unreacted prodrug 
concentration by spectrofluorimetric analysis (Wallac 1420 Victor2TM, Pekin-
Elmer, USA; λ = 488nm). TAP binding efficiency was easily calculated as 
follows: 
 
Where η is the binding efficiency, m0 the total TAP mass, Cw the concentration 
of the washed TAP and Vw the washed volume. 
4.3.6. Characterization of TAP NPs 
Mean size, size distribution and zeta-potential of NPs were determined by 
triplicate laser light scattering measurements (Zetasizer Nano ZS, Malvern 
Instruments, UK) on 1 % w/v NP suspensions. NP morphology was analyzed by 
transmission electron microscopy (TEM EM208S, Philips, The Netherlands) by 
placing 10 μL of NP suspensions sample on a TEM grid, which was then allowed 
to air dry for 5 minutes.  
4.3.7. In vitro cleavage assay of TAP-conjugated nanoparticles  
In vitro release of Dox from 200 nm NPs was evaluated in MMP2 buffer 
solution; the enzyme was activated with p-aminophenylmercuric acetate 
(APMA) as described in the following: 10 mM solution of APMA, (3.9 mg) in 
 
0
0100%
m
VCm ww 
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0.1 M NaOH (1 mL) was diluted with 50 mM Tris•HCl buffer (99 mL, pH 7.5). 
The pH of the obtained solution was adjusted to pH 7.2. MMP2 solutions in 
buffer (2 mL; 50 mM HEPES, 200 mM NaCl, 10 mM CaCl2, 1 mM ZnCl2, pH 
7.4) were activated for 3 h at 37°C to obtain final enzyme concentrations of 0.1, 
0.5, 1, 5, 10, 20 and 40 nM. For release tests, 100 μl of NP suspension (200 nm 
size) were first centrifuged at 13,000 rpm for 30 min. Then, the supernatant was 
carefully removed, and finally 200 μL of blank buffer or activated MMP2 buffer 
(at the given enzyme concentrations) were added. NPs were resuspended by 
vortexing for 5 min and all the tubes were placed in a thermostatic bath at 37°C 
under agitation at 100 rpm (HT TR-225, INFORS HT Corp., Switzerland). At 
scheduled time intervals, the samples were centrifuged at 13,000 rpm for 30 min 
and the supernatant was analyzed for Dox content by spectrofluorimetric assay. 
Experiments were run in triplicate. The linearity of the response was verified 
over the 0 – 2 µg/mL concentration range (r2 > 0.99). 
4.3.8. Cell culture 
To test the biological effect of the NPs, human fibrosarcoma cells (HT1080), 
primary human dermal fibroblasts (HDF) and primary human umbilical vein 
endothelial cells (HUVECs) were used. The latter were isolated by collagenase 
treatment of human umbilical veins and cultured in human endothelial-SFM 
basal growth medium (Gibco) supplemented with 20 % fetal bovine serum (FBS, 
Gibco), 100 U/mL penicillin, 100 mg/mL streptomycin and 1 X endothelial cell 
growth factor (ECGF, Sigma). The HT1080 cells were cultured with complete 
medium, composed of Eagle's minimal essential medium (EMEM) supplemented 
with 10 % FBS, 100 U/mL penicillin, 100 mg/mL streptomycin. The HDF cells 
were cultured with EMEM supplemented with 20 % FBS, 100 U/mL penicillin, 
100 mg/mL streptomycin and 2 X non essential amino-acids. Cells were 
incubated in a humidified controlled atmosphere with 95 % to 5 % ratio of 
air/CO2, at 37°C. Medium was changed every 2-3 days. All experiments were 
performed in triplicate.  
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4.3.9. Cytotoxicity assay 
Adherent cells were seeded in 96 well microplates at a density of 1 * 10
4
 
cells/well at a final volume of 100 µL and incubated for 24 h in a humidified 
atmosphere at 37 °C and 5 % CO2 to obtain a subconfluent monolayer. Cells 
were treated with Dox free at final concentration of 4 µg mL
-1
 in cell culture 
medium and placebo polystyrene NPs as positive and negative controls, 
respectively. In particular, cells were incubated with TAP NPs at a concentration 
that allowed a final Dox release of 4 µg mL
-1
 after 24h incubation with MMP2 
enzyme, according to the release kinetic curve (Fig. 4B). TAP NPs were simply 
added to cell culture medium or pre-treated with 40 nM MMP2 activated enzyme 
as described above. All samples were in a final volume of 100 µl. The metabolic 
activity of all cell cultures was determined after 1, 2, 5 and 7 days of exposure by 
using standard Alamar Blue assay (Invitrogen). Briefly, after incubation time, 
cells were washed with PBS and 150 µl of Dulbecco’s modified Eagle’s medium 
without phenol red (Gibco), containing 10 vol % Alamar Blue reagent, was 
added to each well and samples were incubated for 4 hours at 37 °C. The solution 
was subsequently removed from the wells and analyzed with a 
spectrophotometer (1420 Victor, Perkin Elmer) at wavelengths of 570 and 600 
nm. Data represent the cell viability percentage of treated cells normalized to non 
treated cells. 
4.3.10. Confocal microscopy for nanoparticle uptake  
HT1080 cells were incubated with pre-treated and non pre-treated TAP NPs at 
the same concentrations used for cytotoxicity assay for 24 hours at 37 °C in 5 % 
CO2. Then, samples were washed two times with PBS to remove non 
internalized NPs and fixed with paraformaldehyde 4 % for 20 min. Finally, cell 
nuclei were stained with DAPI. Samples were observed by confocal multiphoton 
microscope system (Leica TCS SP5 MP) with a 63 X oil immersion objective. 
Images were acquired with a resolution of 1024x1024 pixels.  
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 4.4. RESULTS 
4.4.1. TAP NP synthesis  
Purified peptides were obtained with yields > 90 %. Figure 1 reports the results 
of the synthesis of the MMP2 sensitive peptides, of the Fmoc-PEG-MMP2 
adduct and of the TAP. Figure 1A shows, the HPLC chromatogram of Peptide A 
(Fig. 1B). Subsequently, the binding of Fmoc-PEG-COOH on NH2 terminus of 
peptide on resin was confirmed by RP-HPLC analysis of the crude conjugate, 
following the specific Fmoc absorbance appearance at 301 nm into second peak 
(panel C) (containing conjugate Fmoc-PEG-Peptide). The yield of PEG coupling 
on resin-peptides was about 20-25 %. The purified Fmoc-conjugate was then 
bound to Dox (Figs. 1E and 1F). Fmoc-TAP synthesis was verified by the 
absorbance appearing at 301 nm (Fmoc) and at 485 nm (Dox) in the third peak at 
17 min (panel E). 
 
Figure 1. Step synthesis and characterization of TAP. A) HPLC profile of MMP2 sensitive 
peptide; B) chemical structure of MMP 2A sensitive peptide; C) HPLC profile of reaction mix 
from Fmoc-PEG linked to MMP 2A peptide; the formation of the conjugate is highlighted by 
peak appearance at 15 min, that show Fmoc absorbance at 301 nm; D) chemical structure of 
Fmoc-PEG-MMP 2A sensitive peptide conjugate; E) HPLC profile of reaction mixture after 
ligation of Doxorubicin on conjugate added with MMP 2A sensitive peptide; F) Chemical 
structure of Fmoc-TAP product synthesized. 
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PEG amine group was then de-blocked from Fmoc moiety through piperidine 
treatment and purified. Finally, TAP was conjugated on NPs with a 20-30% 
binding efficiency (Table 1).  
 
Table 1 - Size and ζ-potential of Dox-conjugated PS-NPs. * PDI < 0.2 
4.4.2. NP characterization  
Fig. 2 shows the transmission electron microscope (TEM) images of the as-
prepared, randomly distributed, blank (Fig. 2A) and TAP-conjugated PS-NPs 
with A and B peptides (Figs. 2B and 2C, respectively). The insets show single 
representative NPs.  
 
Figure 2. TEM images of: A) unmodified PS-NPs; B) TAP-conjugated NPs by peptide A; C) 
and TAP- conjugated NPs by peptide B.  
As shown in Fig. 3 and summarized in Table 1, the conjugation of the TAP to 
PS-NPs causes negligible changes in diameter of the NPs (from about 177 to 
about 180 nm) compared to the blank PS NPs. In contrast, the conjugation with 
TAP entailed considerable variations of the ζ-potential of the NPs, which 
changed from about -50 mV to about -20 mV when the conjugation was carried 
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out with both A and B peptides. This suggests that the addition of the hydrophilic 
segments of the PEG can partially mask the terminal carboxyl group of PS-NPs 
and does not affect NP colloidal stability. 
4.4.3. Doxorubicin release kinetics from TAP NPs  
In vitro release profiles of Dox from TAP MMP-sensitive NPs were evaluated by 
a standard sampling-separation method as described in the Materials and 
Methods section. Dox release was investigated in MMP-free medium (Fig. 3A) 
as well as at three different MMP2 concentrations (10, 20 and 40 nM), (Figs. 3B 
and 3C). In the absence of the enzyme, Dox was released very slowly and, after 
5 days of incubation in enzyme-free buffer, the percentage of the released drug 
was 1.5 % (peptide A) and 7.3 % (peptide B). On the contrary, the MMP2 
presence within the release medium induced a much faster rapid Dox release, 
which reached a plateau after approximately 10 h at 37 °C. The increment of Dox 
released percentage was 40-50 fold higher in the case of TAP-A NPs, and 70-80 
fold higher for TAP-B NPs compared to the case of MMP2-free releae medium. 
In particular, when the TAP was conjugated to the NPs through the peptide A, 
the released percentage of Dox after 24 h of incubation was approximately 
between 19 % (concentration 10 nM) and 49 % (concentration 40 nM). In the 
case of the TAP conjugated to NPs by peptide B, the release after 24 h was 
between about 88 % (concentration 10 nM) and 95 % (20 and 40 nM), thus 
showing that peptide B is more active than peptide A in inducing faster Dox 
release. It must be also noticed that in both TAP NP formulations, the enzyme 
effect reaches a saturation above 20 nM, while, below 20 nM MMP2 
concentration, a reduction in drug release rate was observed. 
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Figure 3. In vitro release profiles of Dox release from TAP-conjugate PS-NPs in: A) PBS; B) MMP-
activated buffer, peptide A; C) MMP-activated buffer, peptide B.  
In particular, analyzing dose-dependent release, as shown in Fig. 4, below 1 nM 
enzyme concentration a drastic decrease in drug release profile was observed 
after 2h incubation, while above 1 nM a slight increase of Dox release until 20 
nM was obtained, and this effect was more evident in the case of TAP-B NPs.  
 
Figure 4. In vitro release profiles of Dox released from TAP-conjugate PS-NPs after 2h incubation 
with different  MMP2 enzyme concentrations.  
 
4.4.4. TAP NP cytotoxicity and uptake 
The cytotoxic effect of TAP NP delivery systems was evaluated by an in vitro 
Alamar Blue assay on HT1080, HDF and HUVEC cells. Fig. 5 shows the cell 
viability percentage of treated cells normalized to non-treated cells. As expected, 
a significant cytotoxic effect between 1 day and 7 days was observed for free 
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Dox at 4 μg mL-1. The cytotoxic effect was higher for tumor than healthy and 
primary cells. In particular, HT1080 cell viability drastically decreased already 
after 24 hours of incubation with the free drug up to 36 %. On the other hand, a 
slighter reduction of cell viability percentages was detected for HDF and 
HUVECs (66 % and 73 %, respectively). Furthermore, this gap continued along 
the incubation time. Also TAP NPs, pre-treated for 24h with MMP2 activated 
enzyme, showed a cytotoxic effect on all the cell types. In particular, in 
agreement with Dox release kinetics, the cytotoxic effect was more evident for 
NPs functionalized with peptide B compared to peptide A. Moreover, the 
cytotoxic response increases by increasing incubation time. However, the 
decrease of cell viability was less evident than free Dox, probably due to the 
presence of aminoacidic residues bound to drug molecule after the enzyme 
cleavage that reduced Dox effects. On the other hand, no cytotoxic effects until 
48 hours were observed when TAP NPs, without enzyme pre-treatment, were 
used. Increasing incubation time, a very slight reduction in cell viability, in 
particular for HT1080 cells, was detected.  
 
Figure 5. Cytotoxicity assay of TAP NPs and MMP2 pre-treated TAP NPs in HT1080, HDF 
and HUVECs cells follow until one week of incubation. Cell viability was expressed as 
percentage respect to the non-treated control cells. 
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These results probably suggested that NPs could be entrapped in the lysosome 
where the acid pH (5.0) could cut the link between NPs and peptide with 
consequent drug release. Finally, control experiments, carried out by using 
placebo NPs, showed no cytotoxic effects in all cell lines up to 7 days of culture. 
In order to verify the cellular uptake of Dox, HT1080 cells were observed by 
confocal microscope after 48 hours of incubation with TAP NPs and MMP2 pre-
treated TAP NPs (Fig. 6). For cells incubated with MMP2 pre-treated TAP NPs, 
as expected, the images showed both a diffuse and spotted fluorescence signal 
within cell cytoplasm, indicating the partial release of free Dox (fig. 6 A and B). 
This Dox intracellular distribution was more evident for TAP-B NPs than TAP-A 
NPs. Interestingly, also for cells incubated with non pre-treated TAP NPs, an 
intracellular fluorescence was detected (fig. 6 C and D). However, Dox was 
distributed in discrete spots, mainly localized in perinuclear region, and no 
diffused free Dox was observed within the cytoplasm.  
 
Figure 6. Confocal images of HT1080 cells after 48 h incubation with MMP2 pre-treated TAP-
A NPs and TAP-B NPs (A and B, respectively) and TAP-A NPs and TAP-B NPs (C and D, 
respectively). Blu: nuclei. Green: Dox. Magnification bar: 20 µm. 
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4.5. DISCUSSION 
The incorporation of stimuli-responsive portions in engineered NPs is promising 
in achieving controlled and localized release of drugs, offering the chance to 
improve their therapeutic profiles [16, 20, 33, 35]. In fact, in the tumor 
microenvironment, significant changes in the production of some specific 
extracellular proteins occur. Among these proteins, MMP2 and MMP9 play a 
major role in the degradation of tumor extracellular matrix (ECM), and are 
therefore involved in the invasion, progression and metastasis of manifold human 
tumors. In particular, MMP2 is overexpressed in many cancers such as breast, 
colorectal, lung, liver, prostate, pancreas and ovary [33].  
In this context, the main focus of this study was the production of model NPs 
decorated on the surface with suitable tumor-activated prodrugs TAPs, and the 
key elements of these NPs were the enzyme-responsive polymers (PEG – Pep A 
and PEG – Pep B) which governed Dox release through sensitiveness to MMP2 
upregulation [36, 37]. The produced nanodevices have been designed with the 
purpose of transporting cytotoxic drugs in safe manner through tissues that do 
not overexpress MMP2 enzyme and release the conjugated drug only in tissues 
overexpressing MMP2. The latter enzyme has been selected as the trigger for the 
release of the drug. It must also be underlined that specific and local drug release 
from NPs is a difficult task due to biochemical and physical obstacles present in 
tumor tissue architecture. Therefore, in this work we designed a tumor activated 
prodrug by using MMP2 sensitive peptide sequences, linked to Dox and 
conjugated to PS NPs, in order to have drug release triggered by specific 
enzymatic cleavage. Drug release from these is controlled by peptide enzymatic 
cleavage once the produced devices are in a MMP-overexpressing environment. 
The control of drug release rate after in situ cleavage of the drug-peptide bond 
may result in therapeutic levels of the drug, which is highly desirable for local 
drug delivery at tumor sites. In this study, MMP-sensitive NPs were tested for 
drug release triggered by enzymatic attack, which may be potentially useful in 
the achievement of effective local drug delivery for cancers. In particular, NPs 
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were placed in media simulating the elevated MMP2 concentrations associated 
with some cancers [38]. In the presence of nanomolar concentrations of MMP2, 
Dox was rapidly released, while in blank buffer solution the drug was released 
very slowly. The marked increase in drug release from the MMP-sensitive NPs 
suggests its potential as a bio responsive local drug delivery platform to be 
applied in cancer drug delivery.  
Moreover, the TAP-activated PS NPs were expected to release the conjugated 
drug at a rate which is dependent on the enzyme concentration in the external 
medium until the drug is exhausted. In particular, in a very narrow range of 
enzyme concentration, Dox release rate is drastically changed, approaching a sort 
of on-off mechanism. Thus, the definition of the threshold enzyme concentration 
triggering Dox release is of vital importance. Furthermore, finding out the 
enzyme concentration within target tissue is another major task since it defines 
the usefulness of NPs themselves. Our results suggest the presence of an enzyme 
threshold dose, corresponding to approximately 1 nM (Fig. 4), and a linear 
dependence of Dox release on enzyme concentration in the range from 1 nM to 
20 nM. This effect was more evident in the case of TAP-B NPs, thus showing 
that in the release experimental conditions peptide B is more sensitive to enzyme 
concentration compared to peptide A. Indeed, peptide B shows a steepest 
saturation curve, probably due to its major affinity constant, closely depending 
on substrate concentration, while Pep A is not very sensitive to enzyme amount 
into analysis range. Furthermore, we hypothesized that the TAP-B NP higher 
activity and more sensitivity to enzyme concentration than TAP-A NPs could be 
due to peptide B longer chain that results more available for proteolytic cleavage 
into the whole NP structure.  
The specificity of TAP-conjugated NPs in Dox release was also observed by 
cytotoxicity experiments. Indeed, TAP NPs showed a cytotoxic effect on tumor 
cell line and primary cells only when pre-treated with activated MMP2 enzyme. 
In addition, the cytotoxic effect was more evident for NPs functionalized with 
peptide B compared to peptide A, in agreement with the observed drug release 
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kinetics. However, the decrease of cell viability was less evident than free Dox, 
probably due to the presence of an aminoacidic residue tail bound to drug 
molecule after the enzyme cleavage, which that partially reduced specific Dox 
effects. On the other hand, in the absence of MMP2, no cytotoxic effect was 
observed on all the three cell types used up to 2 days of incubation, even though 
the cells could internalize the Dox with and without MMP2 pre-treatment. This 
could be reasonably ascribed to a reduced cytotoxic effect of Dox when the drug 
is covalently bound to NPs. As well known, Dox can exert its cytotoxic activity 
by blocking topoisomerase II activity only when it enters cell nucleus [39, 40]. 
On the contrary when the drug is covalently bound to the NPs, it presents a 
reduced conformational freedom, and therefore an inferior ability to cross nuclear 
membrane and to inhibit the enzyme topoisomerase II.  
Taken all together, our results clearly indicate that Dox, despite its high 
cytotoxicity when in the free state, can be safely transported through non-
overexpressing MMP2 enzyme once it is bound to NPs through enzyme-sensitive 
TAPs. The release of the drug, and therefore its desired cytotoxic action towards 
tumor cells could be induced only in the presence of MMP2 at approximately 
nanomolar concentrations.  
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4.6. CONCLUSIONS 
In this work, MMP-sensitive, TAP-conjugated NPs for enzyme-mediated release 
of cytotoxic drugs have been successfully synthesized by binding two MMP2-
sensitive peptides to Dox and a PEG segment. The resulting adduct was in turn 
tethered to the surface of 200 nm model PS NPs. Results clearly indicate that 
Dox was not released in the absence of the enzyme and that, hence, drug release 
could be triggered only when MMP2 was present. Specifically, higher release 
rates were observed when NPs were functionalized with peptide B, and with an 
increasing MMP2 concentration in the release medium. The enzyme effect was 
basically saturated above 10 nM concentration, and basically similar Dox release 
rates were observed over this concentration.  
The produced NPs were cytotoxic against all the cell lines used in this study, 
when are pre-treated with enzyme, with a stronger effect when NPs were 
functionalized with peptide B. However, the cytotoxicity of TAP NPs was in all 
cases lower compared to the free Dox. Interestingly, TAP NPs were not cytotoxic 
in the absence of MMP pre-treatment, even if the devices could be internalized 
within the cells. Our results showed that Dox was not released from TAP NPs in 
the absence of MMP2 and hence the cytotoxicity could be elicited by 
overexpressed enzyme. A critical issue is the definition of the actual enzyme 
concentrations in vivo which will determine the applicability of these MMP-
sensitive NPs. The release of the drug, and therefore its desired cytotoxic action 
towards tumor cells, could be induced only in the presence of MMP2 at about 1 
nM concentrations. Taken all together, our results are promising in the light of 
translating the same TAP production technology to biodegradable systems 
intended for the targeted delivery of cytotoxic anticancer drugs. 
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CHAPTER 5 
5.1. CONCLUSIONS 
The application of nanoparticles to drug delivery demonstrated to have significant 
impact on many areas of medicine. However, drugs delivered inappropriately to healthy 
tissues or organs can produce off-target and unwanted side effects that can impede to 
reach the most effective dose in the target sites. The overcoming of these limitations 
requires a precise control of NP interstitial diffusion and cellular uptake. In this context, 
this thesis highlighted the importance of defining the NP optimal physicochemical 
characteristics useful for a rational design finalized to a more specific drug delivery in 
tumor tissues.   
For a best understanding of NPs behaviour and cellular uptake, a 3D culture model 
system that better mimics the native environment in which cells reside was reproduced. 
To this aim, matrices made up of collagen type I were prepared, and different cell lines 
were embedded in this network of fibers. The results obtained in this study 
demonstrated that not only size, but also surface charge influenced the NP diffusivity 
and consequently their cellular uptake in a 3D system. Depending on NP formulation 
and size, smaller NPs diffused better in a 3D collagen matrix and were more efficiently 
internalized by several cell types. Nevertheless, surface charge also influenced NP 
behaviour. In fact, cationic NPs not only are internalized by cells in an amount 
comparable to those of small carriers, but they also diffuse freely in a 3D matrix, 
without any apparent hindrance. On the contrary, increasing the negative charge at the 
NP surface drastically promotes their interaction with the matrix, lowering the 
efficiency by which they reach the cells. The same results, as regarding NP size, were 
observed for biodegradable NPs made up of PELGA polymers and loaded with DOX. 
Our data showed a fundamental contribution of sub < 100 nm nanoparticles on the cell 
death rate, particularly in a 3D collagen matrix.  
I also developed a design of a novel carrier able to release DOX under the action of the 
MMP2 enzyme, which is over-expressed in tumor tissues. The results confirmed that 
NP cytotoxic effects can be specifically triggered by MMP2 cleavage, indicating that 
this type of nanocarriers could carry DOX more specifically in the target tumor tissues. 
120 
 
Collectively, the data obtained indicate that a better understanding of the interaction 
between NP and tumor microenvironment is necessary to optimize the control the side-
adverse effects and increase both the therapeutic efficiency and specificity. 
 
 
